# Patent

## Title
MicroRNA fingerprints during human megakaryocytopoiesis

## Abstract

Described herein is a method of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of U.S. patent application Ser. No. 13/169,184, having a 371 filing date of Jun. 27, 2011, now allowed, which claims priority to parent U.S. patent application Ser. No. 12/293,471, having a 371 filing date of Oct. 9, 2008, now U.S. Pat. No. 7,985,584 issued Jul. 26, 2011, which is a national stage application filed under 37 CFR §1.371 of international application PCT/US2007/006824 filed Mar. 19, 2007, which claims priority to U.S. Provisional Application Ser. No. 60/743,585 filed Mar. 20, 2006, the entire disclosures of which are expressly incorporated herein by reference.


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
The invention was supported, in whole or in part, by National Institutes of Health Program Project Grants PO1CA76259, PO1CA16058, PO1CA81534 and P01CA16672. The Government has certain rights in the invention.


BACKGROUND OF THE INVENTION
MicroRNAs (miRNAs) are a small non-coding family of 19-25 nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNA) in a sequence specific manner, inducing translational repression or mRNA degradation depending on the degree of complementarity between miRNAs and their targets (Bartel, D. P. (2004) Cell 116, 281-297; Ambros, V. (2004) Nature 431, 350-355). Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. Indeed, miRNAs are involved in the regulation of gene expression during development (Xu, P., et al. (2003) Curr. Biol. 13, 790-795), cell proliferation (Xu, P., et al. (2003) Curr. Biol. 13, 790-795), apoptosis (Cheng, A. M., et al. (2005) Nucl. Acids Res. 33, 1290-1297), glucose metabolism (Poy, M. N., et al. (2004) Nature 432, 226-230), stress resistance (Dresios, J., et al. (2005) Proc. Natl. Acad. Sci. USA 102, 1865-1870) and cancer (Calin, G. A, et al. (2002) Proc. Natl. Acad. Sci. USA 99, 1554-15529; Calin, G. A., et al. (2004) Proc. Natl. Acad. Sci. USA 101, 11755-11760; He, L., et al. (2005) Nature 435, 828-833; and Lu, J., et al. (2005) Nature 435:834-838).
There is also strong evidence that miRNAs play a role in mammalian hematopoiesis. In mice, miR-181, miR-223 and miR-142 are differentially expressed in hematopoietic tissues, and their expression is regulated during hematopoiesis and lineage commitment (Chen, C. Z., et al. (2004) Science 303, 83-86). The ectopic expression of miR-181 in murine hematopoietic progenitor cells led to proliferation in the B-cell compartment (Chen, C. Z., et al. (2004) Science 303, 83-86). Systematic miRNA gene profiling in cells of the murine hematopoietic system revealed different miRNA expression patterns in the hematopoietic system compared with neuronal tissues, and identified individual miRNA expression changes that occur during cell differentiation (Monticelli, S., et al. (2005) Genome Biology 6, R71). A recent study has identified down-modulation of miR-221 and miR-222 in human erythropoietic cultures of CD34+ cord blood progenitor cells (Felli, N., et al. (2005) Proc. Natl. Acad. Sci. USA. 102, 18081-18086). These miRNAs were found to target the oncogene c-Kit. Further functional studies indicated that the decline of these two miRNAs in erythropoietic cultures unblocks Kit protein production at the translational level leading to expansion of early erythroid cells (Felli, N., et al. (2005) Proc. Natl. Acad. Sci. USA. 102, 18081-18086). In line with the hypothesis of miRNAs regulating cell differentiation, miR-223 was found to be a key member of a regulatory circuit involving C/EBPa and NFI-A, which controls granulocytic differentiation in all-trans retinoic acid-treated acute promyelocytic leukemic cell lines (Fazi, F., et al. (2005) Cell 123, 819-831).
miRNAs have also been found deregulated in hematopoietic malignancies. Indeed, the first report linking miRNAs and cancer involved the deletion and down regulation of the miR-15a and miR-16-1 cluster, located at chromosome 13q14.3, a commonly-deleted region in chronic lymphocytic leukemia (Calin, G. A, et al. (2002) Proc. Natl. Acad. Sci. USA 99, 1554-15529). High expression of miR-155 and host gene BIC was also reported in B-cell lymphomas (Metzler M., et al. (2004) Genes Chromosomes and Cancer 39; 167-169). More recently it was shown that the miR-17-92 cluster, which is located in a genomic region of amplification in lymphomas, is overexpressed in human B-cell lymphomas and the enforced expression of this cluster acted in concert with c-MYC expression to accelerate tumor development in a mouse B cell lymphoma model (He, L., et al. (2005) Nature 435, 828-833). These observations indicate that miRNAs are important regulators of hematopoiesis and can be involved in malignant transformation.
Platelets play an essential role in hemostasis and thrombosis. They are produced from in large numbers from their parent cells, bone marrow megakaryocytes, and arise from fragmentation of the cytoplasm. Only recently has the molecular basis of what may turn out to be a large family of related disorders affecting platelet production started to be defined. If the level of circulating platelets drops below a certain number (thrombocytopenia), the patient runs the risk of catastrophic hemorrhage. Patients with cancer who have received chemotherapy or bone marrow transplants usually have thrombocytopenia, and the slow recovery of platelet count in these patients has been a concern. The demand for platelet units for transfusion has been steadily increasing primarily because of the need to maintain a certain platelet level in such patients with cancer or those undergoing major cardiac surgery.
Identification of microRNAs that are differentially-expressed in cancer cells (e.g., leukemia cells) may help pinpoint specific miRNAs that are involved in cancer and other disorders (e.g., platelet disorders). Furthermore, the identification of putative targets of these miRNAs may help to unravel their pathogenic role. In particular, discovering the patterns and sequence of miRNA expression during hematopoietic differentiation may provide insights about the functional roles of these tiny non-coding genes in normal and malignant hematopoiesis.
There is a need for novel methods and compositions for the diagnosis, prognosis and treatment of cancer, myeloproliferative disorders and platelet disorders (e.g., inherited platelet disorders).
SUMMARY OF THE INVENTION
The present invention is based, in part, on the identification of specific miRNAs that are involved in megakaryocytic differentiation and/or have altered expression levels in cancerous cells (e.g., in acute megakaryoblastic leukemia (AMKL cell lines)). In the present study, the miRNA gene expression in human megakaryocyte cultures from bone marrow CD34+ progenitors and acute megakaryoblastic leukemia cell lines was investigated. The results of this analysis indicate that several miRNAs are downregulated during normal megakaryocytic differentiation. The results further demonstrate that these miRNAs target genes involved in megakaryocytopoiesis, while others are over expressed in cancer cells.
Accordingly, the invention encompasses methods of diagnosing or prognosticating cancer and/or a myeloproliferative disorder in a subject (e.g., a human). According to the methods of the invention, the level of at least one miR gene product in a test sample from the subject is compared to the level of a corresponding miR gene product in a control sample. An alteration (e.g., an increase, a decrease) in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in the control sample, is indicative of the subject either having, or being at risk for developing, cancer and/or a myeloproliferative disorder. In one embodiment, the level of the miR gene product in the test sample from the subject is greater than that of the control. In another embodiment, the at least one miR gene product is selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135 and miR-20. In still another embodiment, the at least one miR gene product is selected from the group consisting of miR-101, miR-126, miR-106, miR-20 and miR-135. In yet another embodiment, the at least one miR gene product is selected from the group consisting of miR-106, miR-20 and miR-135. In particular embodiments, the cancer that is diagnosed or prognosticated is a leukemia (e.g., acute myeloid leukemia (e.g., acute megakaryoblastic leukemia)) or multiple myeloma. In other embodiments, the myeloproliferative disorder is selected from the group consisting of essential thrombocytemia (ET), polycythemia vera (PV), myelodisplasia, myelofibrosis (e.g., agnogenic myeloid metaplasia (AMM) (also referred to as idiopathic myelofibrosis)) and chronic myelogenous leukemia (CML).
In another embodiment, the invention is a method of treating a cancer and/or a myeloproliferative disorder in a subject (e.g., a human). In the method, an effective amount of a compound for inhibiting expression of at least one miR gene product selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135 and miR-20 is administered to the subject. In one embodiment, the compound for inhibiting expression of at least one miR gene product inhibits expression of a miR gene product selected from the group consisting of miR-101, miR-126, miR-106, miR-20 and miR-135. In another embodiment, the compound for inhibiting expression of at least one miR gene product inhibits expression of a miR gene product selected from the group consisting of miR-106, miR-20 and miR-135. In particular embodiments, the cancer that is treated is a leukemia (e.g., acute myeloid leukemia (e.g., acute megakaryoblastic leukemia)) or multiple myeloma. In other embodiments, the myeloproliferative disorder is selected from the group consisting of essential thrombocytemia (ET), polycythemia vera (PV), myelodisplasia, myelofibrosis (e.g., agnogenic myeloid metaplasia (AMM)) and chronic myelogenous leukemia (CML).
In another embodiment, the invention is a method of treating a cancer and/or a myeloproliferative disorder associated with overexpression of a MAFB gene product in a subject (e.g., a human). In the method, an effective amount of at least one miR gene product or a variant or biologically-active fragment thereof, which binds to, and decreases expression of, the MAFB gene product, is administered to the subject. In one embodiment, the at least one miR gene product, variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product. In another embodiment, the at least one miR gene product is miR-130a or a variant or biologically-active fragment thereof. Cancers and myeloproliferative disorders suitable for treatment using this method include, for example, those described herein.
In another embodiment, the invention is a method of treating a cancer and/or a myeloproliferative disorder associated with overexpression of a HOXA1 gene product in a subject (e.g., a human). In the method, an effective amount of at least one miR gene product or a variant or biologically-active fragment thereof, which binds to, and decreases expression of, the HOXA1 gene product, is administered to the subject. In one embodiment, the at least one miR gene product, variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product. In another embodiment, the at least one miR gene product is miR-10a or a variant or biologically-active fragment thereof. Cancers and myeloproliferative disorders suitable for treatment using this method include, for example, those described herein.
In one embodiment, the invention is a method of determining and/or predicting megakaryocytic differentiation. In this method, the level of at least one miR gene product in a sample (e.g., a sample from a subject (e.g., a human)) comprising megakaryocyte progeny and/or megakaryocytes is determined. That level is compared to the level of the corresponding miR gene product in a control. An alteration in the level of the at least one miR gene product in the sample, relative to that of the control, is indicative of megakaryocytic differentiation. In one embodiment, the alteration is a decrease in the level of the at least one miR gene product in the sample. In another embodiment, the at least one miR gene product is selected from the group consisting of miR-10a, miR-126, miR-106, miR-010b, miR-130a, miR-130a-prec, miR-124a, miR-032-prec, miR-101, miR-30c, miR-213, miR-132-prec, miR-150, miR-020, miR-339, let-7a, let-7d, miR-181c, miR-181b and miR-017. In still another embodiment, the at least one miR gene product is selected from the group consisting of miR-10a, miR-10b, miR-30c, miR-106, miR-126, miR-130a, miR-132, and miR-143.
The invention further provides pharmaceutical compositions for treating cancer and/or a myeloproliferative disorder. In one embodiment, the pharmaceutical compositions of the invention comprise at least one miR expression-inhibition compound and a pharmaceutically-acceptable carrier. In a particular embodiment, the at least one miR expression-inhibition compound is specific for a miR gene product whose expression is greater in cancer cells (e.g., acute megakaryoblastic leukemia (AMKL) cells) than control cells (i.e., it is upregulated). In one embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135 and miR-20. In another embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-101, miR-126, miR-106, miR-20, and miR-135. In still another embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-106, miR-20 and miR-135. In yet another embodiment, the pharmaceutical composition further comprises at least one anti-cancer agent.
In one embodiment, the invention is a pharmaceutical composition for treating a cancer associated with overexpression of a MAFB gene product and/or a myeloproliferative disorder associated with overexpression of a MAFB gene product. Such pharmaceutical compositions comprise an effective amount of at least one miR gene product and a pharmaceutically-acceptable carrier, wherein the at least one miR gene product binds to, and decreases expression of, the MAFB gene product. In another embodiment, the at least one miR gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product. In still another embodiment, the at least one miR gene product is miR-130a or a variant or biologically-active fragment thereof. In yet another embodiment, the pharmaceutical composition further comprises at least one anti-cancer agent.
In one embodiment, the invention is a pharmaceutical composition for treating a cancer associated with overexpression of a HOXA1 gene product and/or a myeloproliferative disorder associated with overexpression of a HOXA1 gene product. Such pharmaceutical compositions comprise an effective amount of at least one miR gene product and a pharmaceutically-acceptable carrier, wherein the at least one miR gene product binds to, and decreases expression of, the HOXA1 gene product. In another embodiment, the at least one miR gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product. In still another embodiment, the at least one miR gene product is miR-10a or a variant or biologically-active fragment thereof. In yet another embodiment, the pharmaceutical composition further comprises at least one anti-cancer agent.
Various objects and advantages of this invention will become apparent to those skilled in the art from the following detailed description of the preferred embodiment, when read in light of the accompanying drawings.



BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
FIGS. 1A-1D depict Northern Blots and Real Time miRNA-PCR results, which validate microRNA chip data in CD34 progenitor differentiation experiments.
FIG. 1A depicts Northern Blots for miR-130a, miR-10a and miR-223. A loading RNA control was performed with U6.
FIG. 1B is a graph depicting RT-miRNA-PCR for miR-10a, miR-106, miR-126 and miR-130a. miRNA expression is presented as fold difference with respect to CD34+ cells before culture.
FIG. 1C is a graph depicting temporal expression of miR-223 by microarray.
FIG. 1D is a graph depicting temporal expression of miR-15-1 and miR-16-1 by RT-miRNA PCR.
FIGS. 2A-2C demonstrate that MAFB is a target of miR-130a.
FIG. 2A depicts MAFB mRNA and protein expression data in CD34+ progenitors induced to megakaryocytic differentiation. β-Actin was used for RT-PCR and Western blot loading controls.
FIG. 2B is a graph depicting relative repression of luciferase activity in MEG01 cells co-transfected with miR-10a and PGL3 3′UTR MAFB, miR-10a with PGL3 3′UTR, miR-10a seed match mutated and scramble with mutated, and wild type 3′UTR MAFB.
FIG. 2C depicts Western blots of MAFB total protein lysates in K562 cells transfected with miR-130a and scramble.
FIGS. 3A-3G demonstrate that MiR-10a downregulates HOXA1 by mediating RNA cleavage.
FIG. 3A is a graph depicting RT-PCR results for HOXA1 gene expression in differentiated megakaryocytes (Relative amount of transcript with respect to CD34+ progenitors at baseline).
FIG. 3B is a Western blot showing hoxa1 protein expression in differentiated megakaryocytes.
FIG. 3C is a graph depicting relative repression of luciferase activity of HOXA1 3′ UTR cloned PGL3 reporter plasmid when co-transfected with miR-10a and control scramble.
FIG. 3D is a schematic showing complementarity between miR-10a (SEQ ID NO: 322) and the HOXA1 3′UTR (SEQ ID NO: 507) as predicted by PICTAR.
FIG. 3E depicts RT-PCR results for miR-10a gene expression in scramble and miR-10a precursor transfected K562 cells.
FIG. 3F depicts RT-PCR results for HOXA1 gene expression in scramble and miR-10a precursor transfected K562 cells.
FIG. 3G is a Western blot showing HOXA1 expression in K562 cells transfected with control scramble and precursor miR-10a.
FIGS. 4A and 4B show phenotypic characterization results of in vitro-differentiated CD34+ progenitors.
FIG. 4A depicts May-Giemsa stains that were performed on cytospin preparations from CD34+ progenitors in culture at different days of culture (day 6, day 10, day 12 and day 14). At day 4, most of the cells were immature, as evidenced by the high nucleous:cytoplasmic ratio. Larger and multinuclear cells were observed by day 10. At day 14, predominantly larger, polyploid cells with long cytoplasmic processes and numerous membrane blebs with invaginations and vacuoles (original magnification 400×) were observed.
FIG. 4B depicts FACS analysis of CD34 in vitro-differentiated megakaryocytes. The membrane phenotype of CD34+ progenitor cells that are grown in culture is shown. Cells were harvested at days 10 (D+10), 14 (D+14) and 16 (D+16) and were analyzed by single fluorescent labeling using an anti-CD41 antibody, an anti-CD61a antibody, an anti-CD42a antibody and their respective isotype monoclonal antibodies (D+10 isotype; D+14 isotype; D+16 isotype). Double labeling was performed with anti-CD41a and CD61b monoclonal Abs at day 14 only.
FIG. 5 is a graph depicting RT-PCR expression results for miR-20 and miR-17 in differentiated megakaryocytes. The results are presented as fold difference with respect to CD34+ cells at baseline after normalization with 18S and delta Ct calculations.
FIG. 6A is a graph depicting temporal expression of miR-16-1 during megakaryocytic differentiation. The absolute expression value of miR-16-1 was determined by a per-chip median normalization.
FIG. 6B is a graph depicting temporal expression of miR-142 during megakaryocytic differentiation. The absolute expression value of miR-142 was determined by a per-chip median normalization.
FIG. 6C is a graph depicting temporal expression of miR-181b during megakaryocytic differentiation. The absolute expression value of miR-181b was determined by a per-chip median normalization.
FIG. 7 is a Northern Blot of total RNA obtained from K562 cells transfected with miR-130a precursor and scramble sequences hybridized with the probe for miR-130a. An RNA loading control was performed using U6 hybridization.
FIG. 8 is a schematic depicting microRNAs that are located in the HOXA, HOXB, HOXC and HOXD gene clusters.
FIG. 9A is a graph depicting HOXB4 gene expression in differentiated megakaryocytes. RT-PCR results for HOXB4 are shown as fold difference in the expression level with respect to CD34+ progenitors at baseline (before culture).
FIG. 9B is a graph depicting HOXB5 gene expression in differentiated megakaryocytes. RT-PCR results for HOXB5 are shown as fold difference in the expression levels with respect to CD34+ progenitors at baseline (before culture).
FIG. 10 is a graph depicting microRNA expression in acute megakaryoblastic cell lines by RT-PCR. Results are expressed as fold difference with respect to CD34-differentiated megakaryocytes after normalization with 18S and delta Ct calculations.



DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention is based, in part, on the identification of specific microRNAs (miRNAs) that are involved in megakaryocytic differentiation and/or have altered expression levels in cancerous cells (e.g., in acute megakaryoblastic leukemia (AMKL cell lines)). The invention is further based, in part, on association of these miRNAs with particular diagnostic, prognostic and therapeutic features. As described and exemplified herein:
i) particular miRNA are downregulated during megakaryocytic differentiation;
ii) the transcription factor MAFB is a target for miR-130a;
iii) miR-10a expression parallels that of HOXB gene expression;
iv) miR-10a downregulates HOXA1 expression; and
v) particular miRNA are upregulated in cancerous cells (e.g., acute megakaryoblastic leukemia (AMKL) cells).
As used herein interchangeably, a “miR gene product,” “microRNA,” “miR,” “miR” or “miRNA” refers to the unprocessed or processed RNA transcript from a miR gene. As the miR gene products are not translated into protein, the term “miR gene products” does not include proteins. The unprocessed miR gene transcript is also called a “miR precursor,” and typically comprises an RNA transcript of about 70-100 nucleotides in length. The miR precursor can be processed by digestion with an RNAse (for example, Dicer, Argonaut, RNAse III (e.g., E. coli RNAse III)) into an active 19-25 nucleotide RNA molecule. This active 19-25 nucleotide RNA molecule is also called the “processed” miR gene transcript or “mature” miRNA.
The active 19-25 nucleotide RNA molecule can be obtained from the miR precursor through natural processing routes (e.g., using intact cells or cell lysates) or by synthetic processing routes (e.g., using isolated processing enzymes, such as isolated Dicer, Argonaut, or RNAse III). It is understood that the active 19-25 nucleotide RNA molecule can also be produced directly by biological or chemical synthesis, without having to be processed from the miR precursor. When a microRNA is referred to herein by name, the name corresponds to both the precursor and mature forms, unless otherwise indicated.
Tables 1a and 1b depict the nucleotide sequences of particular precursor and mature human microRNAs.







TABLE 1a







Human microRNA Precursor Sequences.









Precursor




Name
Sequence (5′ To 3′)*
SEQ ID NO.












let-7a-1
CACUGUGGGAUGAGGUAGUAGGUUGUAUAGUUUUAGGG
1



UCACACCCACCACUGGGAGAUAACUAUACAAUCUACUGU




CUUUCCUAACGUG



 


let-7a-2
AGGUUGAGGUAGUAGGUUGUAUAGUUUAGAAUUACAUC
2



AAGGGAGAUAACUGUACAGCCUCCUAGCUUUCCU



 


let-7a-3
GGGUGAGGUAGUAGGUUGUAUAGUUUGGGGCUCUGCCC
3



UGCUAUGGGAUAACUAUACAAUCUACUGUCUUUCCU



 


let-7a-4
GUGACUGCAUGCUCCCAGGUUGAGGUAGUAGGUUGUAU
4



AGUUUAGAAUUACACAAGGGAGAUAACUGUACAGCCUC




CUAGCUUUCCUUGGGUCUUGCACUAAACAAC



 


let-7b
GGCGGGGUGAGGUAGUAGGUUGUGUGGUUUCAGGGCAG
5



UGAUGUUGCCCCUCGGAAGAUAACUAUACAACCUACUGC




CUUCCCUG



 


let-7c
GCAUCCGGGUUGAGGUAGUAGGUUGUAUGGUUUAGAGU
6



UACACCCUGGGAGUUAACUGUACAACCUUCUAGCUUUCC




UUGGAGC



 


let-7d
CCUAGGAAGAGGUAGUAGGUUGCAUAGUUUUAGGGCAG
7



GGAUUUUGCCCACAAGGAGGUAACUAUACGACCUGCUGC




CUUUCUUAGG



 


let-7d-v1
CUAGGAAGAGGUAGUAGUUUGCAUAGUUUUAGGGCAAA
8



GAUUUUGCCCACAAGUAGUUAGCUAUACGACCUGCAGCC




UUUUGUAG



 


let-7d-v2
CUGGCUGAGGUAGUAGUUUGUGCUGUUGGUCGGGUUGU
9



GACAUUGCCCGCUGUGGAGAUAACUGCGCAAGCUACUGC




CUUGCUAG



 


let-7e
CCCGGGCUGAGGUAGGAGGUUGUAUAGUUGAGGAGGAC
10



ACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCA




GG



 


let-7f-1
UCAGAGUGAGGUAGUAGAUUGUAUAGUUGUGGGGUAGU
11



GAUUUUACCCUGUUCAGGAGAUAACUAUACAAUCUAUU




GCCUUCCCUGA



 


let-7f-2-1
CUGUGGGAUGAGGUAGUAGAUUGUAUAGUUGUGGGGUA
12



GUGAUUUUACCCUGUUCAGGAGAUAACUAUACAAUCUA




UUGCCUUCCCUGA



 


let-7f-2-2
CUGUGGGAUGAGGUAGUAGAUUGUAUAGUUUUAGGGUC
13



AUACCCCAUCUUGGAGAUAACUAUACAGUCUACUGUCUU




UCCCACGG



 


let-7g
UUGCCUGAUUCCAGGCUGAGGUAGUAGUUUGUACAGUU
14



UGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUG




UACAGGCCACUGCCUUGCCAGGAACAGCGCGC



 


let-7i
CUGGCUGAGGUAGUAGUUUGUGCUGUUGGUCGGGUUGU
15



GACAUUGCCCGCUGUGGAGAUAACUGCGCAAGCUACUGC




CUUGCUAG



 


miR-1b-1-1
ACCUACUCAGAGUACAUACUUCUUUAUGUACCCAUAUGA
16



ACAUACAAUGCUAUGGAAUGUAAAGAAGUAUGUAUUUU




UGGUAGGC



 


miR-1b-1-2
CAGCUAACAACUUAGUAAUACCUACUCAGAGUACAUACU
17



UCUUUAUGUACCCAUAUGAACAUACAAUGCUAUGGAAU




GUAAAGAAGUAUGUAUUUUUGGUAGGCAAUA



 


miR-1b-2
GCCUGCUUGGGAAACAUACUUCUUUAUAUGCCCAUAUG
18



GACCUGCUAAGCUAUGGAAUGUAAAGAAGUAUGUAUCU




CAGGCCGGG



 


miR-1b
UGGGAAACAUACUUCUUUAUAUGCCCAUAUGGACCUGC
19



UAAGCUAUGGAAUGUAAAGAAGUAUGUAUCUCA



 


miR-1d
ACCUACUCAGAGUACAUACUUCUUUAUGUACCCAUAUGA
20



ACAUACAAUGCUAUGGAAUGUAAAGAAGUAUGUAUUUU




UGGUAGGC



 


miR-7-1a
UGGAUGUUGGCCUAGUUCUGUGUGGAAGACUAGUGAUU
21



UUGUUGUUUUUAGAUAACUAAAUCGACAACAAAUCACA




GUCUGCCAUAUGGCACAGGCCAUGCCUCUACA



 


miR-7-1b
UUGGAUGUUGGCCUAGUUCUGUGUGGAAGACUAGUGAU
22



UUUGUUGUUUUUAGAUAACUAAAUCGACAACAAAUCAC




AGUCUGCCAUAUGGCACAGGCCAUGCCUCUACAG



 


miR-7-2
CUGGAUACAGAGUGGACCGGCUGGCCCCAUCUGGAAGAC
23



UAGUGAUUUUGUUGUUGUCUUACUGCGCUCAACAACAA




AUCCCAGUCUACCUAAUGGUGCCAGCCAUCGCA



 


miR-7-3
AGAUUAGAGUGGCUGUGGUCUAGUGCUGUGUGGAAGAC
24



UAGUGAUUUUGUUGUUCUGAUGUACUACGACAACAAGU




CACAGCCGGCCUCAUAGCGCAGACUCCCUUCGAC



 


miR-9-1
CGGGGUUGGUUGUUAUCUUUGGUUAUCUAGCUGUAUGA
25



GUGGUGUGGAGUCUUCAUAAAGCUAGAUAACCGAAAGU




AAAAAUAACCCCA



 


miR-9-2
GGAAGCGAGUUGUUAUCUUUGGUUAUCUAGCUGUAUGA
26



GUGUAUUGGUCUUCAUAAAGCUAGAUAACCGAAAGUAA




AAACUCCUUCA



 


miR-9-3
GGAGGCCCGUUUCUCUCUUUGGUUAUCUAGCUGUAUGA
27



GUGCCACAGAGCCGUCAUAAAGCUAGAUAACCGAAAGU




AGAAAUGAUUCUCA



 


miR-10a
GAUCUGUCUGUCUUCUGUAUAUACCCUGUAGAUCCGAA
28



UUUGUGUAAGGAAUUUUGUGGUCACAAAUUCGUAUCUA




GGGGAAUAUGUAGUUGACAUAAACACUCCGCUCU



 


miR-10b
CCAGAGGUUGUAACGUUGUCUAUAUAUACCCUGUAGAA
29



CCGAAUUUGUGUGGUAUCCGUAUAGUCACAGAUUCGAU




UCUAGGGGAAUAUAUGGUCGAUGCAAAAACUUCA



 


miR-15a-2
GCGCGAAUGUGUGUUUAAAAAAAAUAAAACCUUGGAGU
30



AAAGUAGCAGCACAUAAUGGUUUGUGGAUUUUGAAAAG




GUGCAGGCCAUAUUGUGCUGCCUCAAAAAUAC



 


miR-15a
CCUUGGAGUAAAGUAGCAGCACAUAAUGGUUUGUGGAU
31



UUUGAAAAGGUGCAGGCCAUAUUGUGCUGCCUCAAAAA




UACAAGG



 


miR-15b-1
CUGUAGCAGCACAUCAUGGUUUACAUGCUACAGUCAAG
32



AUGCGAAUCAUUAUUUGCUGCUCUAG



 


miR-15b-2
UUGAGGCCUUAAAGUACUGUAGCAGCACAUCAUGGUUU
33



ACAUGCUACAGUCAAGAUGCGAAUCAUUAUUUGCUGCU




CUAGAAAUUUAAGGAAAUUCAU



 


miR-16-1
GUCAGCAGUGCCUUAGCAGCACGUAAAUAUUGGCGUUA
34



AGAUUCUAAAAUUAUCUCCAGUAUUAACUGUGCUGCUG




AAGUAAGGUUGAC



 


miR-16-2
GUUCCACUCUAGCAGCACGUAAAUAUUGGCGUAGUGAA
35



AUAUAUAUUAAACACCAAUAUUACUGUGCUGCUUUAGU




GUGAC



 


miR-16-13
GCAGUGCCUUAGCAGCACGUAAAUAUUGGCGUUAAGAU
36



UCUAAAAUUAUCUCCAGUAUUAACUGUGCUGCUGAAGU




AAGGU



 


miR-17
GUCAGAAUAAUGUCAAAGUGCUUACAGUGCAGGUAGUG
37



AUAUGUGCAUCUACUGCAGUGAAGGCACUUGUAGCAUU




AUGGUGAC



 


miR-18
UGUUCUAAGGUGCAUCUAGUGCAGAUAGUGAAGUAGAU
38



UAGCAUCUACUGCCCUAAGUGCUCCUUCUGGCA



 


miR-18-13
UUUUUGUUCUAAGGUGCAUCUAGUGCAGAUAGUGAAGU
39



AGAUUAGCAUCUACUGCCCUAAGUGCUCCUUCUGGCAUA




AGAA



 


miR-19a
GCAGUCCUCUGUUAGUUUUGCAUAGUUGCACUACAAGA
40



AGAAUGUAGUUGUGCAAAUCUAUGCAAAACUGAUGGUG




GCCUGC



 


miR-19a-13
CAGUCCUCUGUUAGUUUUGCAUAGUUGCACUACAAGAA
41



GAAUGUAGUUGUGCAAAUCUAUGCAAAACUGAUGGUGG




CCUG



 


miR-19b-1
CACUGUUCUAUGGUUAGUUUUGCAGGUUUGCAUCCAGC
42



UGUGUGAUAUUCUGCUGUGCAAAUCCAUGCAAAACUGA




CUGUGGUAGUG



 


miR-19b-2
ACAUUGCUACUUACAAUUAGUUUUGCAGGUUUGCAUUU
43



CAGCGUAUAUAUGUAUAUGUGGCUGUGCAAAUCCAUGC




AAAACUGAUUGUGAUAAUGU



 


miR-19b-13
UUCUAUGGUUAGUUUUGCAGGUUUGCAUCCAGCUGUGU
44



GAUAUUCUGCUGUGCAAAUCCAUGCAAAACUGACUGUG




GUAG



 


miR-19b-X
UUACAAUUAGUUUUGCAGGUUUGCAUUUCAGCGUAUAU
45



AUGUAUAUGUGGCUGUGCAAAUCCAUGCAAAACUGAUU




GUGAU



 


miR-20
GUAGCACUAAAGUGCUUAUAGUGCAGGUAGUGUUUAGU
46


(miR-20a)
UAUCUACUGCAUUAUGAGCACUUAAAGUACUGC



 


miR-21
UGUCGGGUAGCUUAUCAGACUGAUGUUGACUGUUGAAU
47



CUCAUGGCAACACCAGUCGAUGGGCUGUCUGACA



 


miR-21-17
ACCUUGUCGGGUAGCUUAUCAGACUGAUGUUGACUGUU
48



GAAUCUCAUGGCAACACCAGUCGAUGGGCUGUCUGACAU




UUUG



 


miR-22
GGCUGAGCCGCAGUAGUUCUUCAGUGGCAAGCUUUAUG
49



UCCUGACCCAGCUAAAGCUGCCAGUUGAAGAACUGUUGC




CCUCUGCC



 


miR-23a
GGCCGGCUGGGGUUCCUGGGGAUGGGAUUUGCUUCCUG
50



UCACAAAUCACAUUGCCAGGGAUUUCCAACCGACC



 


miR-23b
CUCAGGUGCUCUGGCUGCUUGGGUUCCUGGCAUGCUGAU
51



UUGUGACUUAAGAUUAAAAUCACAUUGCCAGGGAUUAC




CACGCAACCACGACCUUGGC



 


miR-23-19
CCACGGCCGGCUGGGGUUCCUGGGGAUGGGAUUUGCUUC
52



CUGUCACAAAUCACAUUGCCAGGGAUUUCCAACCGACCC




UGA



 


miR-24-1
CUCCGGUGCCUACUGAGCUGAUAUCAGUUCUCAUUUUAC
53



ACACUGGCUCAGUUCAGCAGGAACAGGAG



 


miR-24-2
CUCUGCCUCCCGUGCCUACUGAGCUGAAACACAGUUGGU
54



UUGUGUACACUGGCUCAGUUCAGCAGGAACAGGG



 


miR-24-19
CCCUGGGCUCUGCCUCCCGUGCCUACUGAGCUGAAACAC
55



AGUUGGUUUGUGUACACUGGCUCAGUUCAGCAGGAACA




GGGG



 


miR-24-9
CCCUCCGGUGCCUACUGAGCUGAUAUCAGUUCUCAUUUU
56



ACACACUGGCUCAGUUCAGCAGGAACAGCAUC



 


miR-25
GGCCAGUGUUGAGAGGCGGAGACUUGGGCAAUUGCUGG
57



ACGCUGCCCUGGGCAUUGCACUUGUCUCGGUCUGACAGU




GCCGGCC



 


miR-26a
AGGCCGUGGCCUCGUUCAAGUAAUCCAGGAUAGGCUGU
58



GCAGGUCCCAAUGGCCUAUCUUGGUUACUUGCACGGGGA




CGCGGGCCU



 


miR-26a-1
GUGGCCUCGUUCAAGUAAUCCAGGAUAGGCUGUGCAGG
59



UCCCAAUGGGCCUAUUCUUGGUUACUUGCACGGGGACGC



 


miR-26a-2
GGCUGUGGCUGGAUUCAAGUAAUCCAGGAUAGGCUGUU
60



UCCAUCUGUGAGGCCUAUUCUUGAUUACUUGUUUCUGG




AGGCAGCU



 


miR-26b
CCGGGACCCAGUUCAAGUAAUUCAGGAUAGGUUGUGUG
61



CUGUCCAGCCUGUUCUCCAUUACUUGGCUCGGGGACCGG



 


miR-27a
CUGAGGAGCAGGGCUUAGCUGCUUGUGAGCAGGGUCCA
62



CACCAAGUCGUGUUCACAGUGGCUAAGUUCCGCCCCCCA




G



 


miR-27b-1
AGGUGCAGAGCUUAGCUGAUUGGUGAACAGUGAUUGGU
63



UUCCGCUUUGUUCACAGUGGCUAAGUUCUGCACCU



 


miR-27b-2
ACCUCUCUAACAAGGUGCAGAGCUUAGCUGAUUGGUGA
64



ACAGUGAUUGGUUUCCGCUUUGUUCACAGUGGCUAAGU




UCUGCACCUGAAGAGAAGGUG



 


miR-27-19
CCUGAGGAGCAGGGCUUAGCUGCUUGUGAGCAGGGUCC
65



ACACCAAGUCGUGUUCACAGUGGCUAAGUUCCGCCCCCC




AGG



 


miR-28
GGUCCUUGCCCUCAAGGAGCUCACAGUCUAUUGAGUUAC
66



CUUUCUGACUUUCCCACUAGAUUGUGAGCUCCUGGAGGG




CAGGCACU



 


miR-29a-2
CCUUCUGUGACCCCUUAGAGGAUGACUGAUUUCUUUUG
67



GUGUUCAGAGUCAAUAUAAUUUUCUAGCACCAUCUGAA




AUCGGUUAUAAUGAUUGGGGAAGAGCACCAUG



 


miR-29a
AUGACUGAUUUCUUUUGGUGUUCAGAGUCAAUAUAAUU
68



UUCUAGCACCAUCUGAAAUCGGUUAU



 


miR-29b-1
CUUCAGGAAGCUGGUUUCAUAUGGUGGUUUAGAUUUAA
69



AUAGUGAUUGUCUAGCACCAUUUGAAAUCAGUGUUCUU




GGGGG



 


miR-29b-2
CUUCUGGAAGCUGGUUUCACAUGGUGGCUUAGAUUUUU
70



CCAUCUUUGUAUCUAGCACCAUUUGAAAUCAGUGUUUU




AGGAG



 


miR-29c
ACCACUGGCCCAUCUCUUACACAGGCUGACCGAUUUCUC
71



CUGGUGUUCAGAGUCUGUUUUUGUCUAGCACCAUUUGA




AAUCGGUUAUGAUGUAGGGGGAAAAGCAGCAGC



 


miR-30a
GCGACUGUAAACAUCCUCGACUGGAAGCUGUGAAGCCAC
72



AGAUGGGCUUUCAGUCGGAUGUUUGCAGCUGC



 


miR-30b-1
AUGUAAACAUCCUACACUCAGCUGUAAUACAUGGAUUG
73



GCUGGGAGGUGGAUGUUUACGU



 


miR-30b-2
ACCAAGUUUCAGUUCAUGUAAACAUCCUACACUCAGCUG
74



UAAUACAUGGAUUGGCUGGGAGGUGGAUGUUUACUUCA




GCUGACUUGGA



 


miR-30c
AGAUACUGUAAACAUCCUACACUCUCAGCUGUGGAAAG
75



UAAGAAAGCUGGGAGAAGGCUGUUUACUCUUUCU



 


miR-30d
GUUGUUGUAAACAUCCCCGACUGGAAGCUGUAAGACAC
76



AGCUAAGCUUUCAGUCAGAUGUUUGCUGCUAC



 


miR-30e
CUGUAAACAUCCUUGACUGGAAGCUGUAAGGUGUUCAG
77



AGGAGCUUUCAGUCGGAUGUUUACAG



 


miR-31
GGAGAGGAGGCAAGAUGCUGGCAUAGCUGUUGAACUGG
78



GAACCUGCUAUGCCAACAUAUUGCCAUCUUUCC



 


miR-32
GGAGAUAUUGCACAUUACUAAGUUGCAUGUUGUCACGG
79



CCUCAAUGCAAUUUAGUGUGUGUGAUAUUUUC



 


miR-33b
GGGGGCCGAGAGAGGCGGGCGGCCCCGCGGUGCAUUGCU
80



GUUGCAUUGCACGUGUGUGAGGCGGGUGCAGUGCCUCG




GCAGUGCAGCCCGGAGCCGGCCCCUGGCACCAC



 


miR-33b-2
ACCAAGUUUCAGUUCAUGUAAACAUCCUACACUCAGCUG
81



UAAUACAUGGAUUGGCUGGGAGGUGGAUGUUUACUUCA




GCUGACUUGGA



 


miR-33
CUGUGGUGCAUUGUAGUUGCAUUGCAUGUUCUGGUGGU
82



ACCCAUGCAAUGUUUCCACAGUGCAUCACAG



 


miR-34-a
GGCCAGCUGUGAGUGUUUCUUUGGCAGUGUCUUAGCUG
83



GUUGUUGUGAGCAAUAGUAAGGAAGCAAUCAGCAAGUA




UACUGCCCUAGAAGUGCUGCACGUUGUGGGGCCC



 


miR-34-b
GUGCUCGGUUUGUAGGCAGUGUCAUUAGCUGAUUGUAC
84



UGUGGUGGUUACAAUCACUAACUCCACUGCCAUCAAAAC




AAGGCAC



 


miR-34-c
AGUCUAGUUACUAGGCAGUGUAGUUAGCUGAUUGCUAA
85



UAGUACCAAUCACUAACCACACGGCCAGGUAAAAAGAUU



 


miR-91-13
UCAGAAUAAUGUCAAAGUGCUUACAGUGCAGGUAGUGA
86



UAUGUGCAUCUACUGCAGUGAAGGCACUUGUAGCAUUA




UGGUGA



 


miR-92-1
CUUUCUACACAGGUUGGGAUCGGUUGCAAUGCUGUGUU
87



UCUGUAUGGUAUUGCACUUGUCCCGGCCUGUUGAGUUU




GG



 


miR-92-2
UCAUCCCUGGGUGGGGAUUUGUUGCAUUACUUGUGUUC
88



UAUAUAAAGUAUUGCACUUGUCCCGGCCUGUGGAAGA



 


miR-93-1
CUGGGGGCUCCAAAGUGCUGUUCGUGCAGGUAGUGUGA
89


(miR-93-2)
UUACCCAACCUACUGCUGAGCUAGCACUUCCCGAGCCCC




CGG



 


miR-95-4
AACACAGUGGGCACUCAAUAAAUGUCUGUUGAAUUGAA
90



AUGCGUUACAUUCAACGGGUAUUUAUUGAGCACCCACUC




UGUG



 


miR-96-7
UGGCCGAUUUUGGCACUAGCACAUUUUUGCUUGUGUCU
91



CUCCGCUCUGAGCAAUCAUGUGCAGUGCCAAUAUGGGAA




A



 


miR-97-6
GUGAGCGACUGUAAACAUCCUCGACUGGAAGCUGUGAA
92


(miR-30*)
GCCACAGAUGGGCUUUCAGUCGGAUGUUUGCAGCUGCCU




ACU



 


miR-98
GUGAGGUAGUAAGUUGUAUUGUUGUGGGGUAGGGAUAU
93



UAGGCCCCAAUUAGAAGAUAACUAUACAACUUACUACU




UUCC



 


miR-99b
GGCACCCACCCGUAGAACCGACCUUGCGGGGCCUUCGCC
94



GCACACAAGCUCGUGUCUGUGGGUCCGUGUC



 


miR-99a
CCCAUUGGCAUAAACCCGUAGAUCCGAUCUUGUGGUGAA
95



GUGGACCGCACAAGCUCGCUUCUAUGGGUCUGUGUCAGU




GUG



 


miR-100-1/2
AAGAGAGAAGAUAUUGAGGCCUGUUGCCACAAACCCGU
96



AGAUCCGAACUUGUGGUAUUAGUCCGCACAAGCUUGUA




UCUAUAGGUAUGUGUCUGUUAGGCAAUCUCAC



 


miR-100-11
CCUGUUGCCACAAACCCGUAGAUCCGAACUUGUGGUAUU
97



AGUCCGCACAAGCUUGUAUCUAUAGGUAUGUGUCUGUU




AGG



 


miR-101-1/2
AGGCUGCCCUGGCUCAGUUAUCACAGUGCUGAUGCUGUC
98



UAUUCUAAAGGUACAGUACUGUGAUAACUGAAGGAUGG




CAGCCAUCUUACCUUCCAUCAGAGGAGCCUCAC



 


miR-101
UCAGUUAUCACAGUGCUGAUGCUGUCCAUUCUAAAGGU
99



ACAGUACUGUGAUAACUGA



 


miR-101-1
UGCCCUGGCUCAGUUAUCACAGUGCUGAUGCUGUCUAUU
100



CUAAAGGUACAGUACUGUGAUAACUGAAGGAUGGCA



 


miR-101-2
ACUGUCCUUUUUCGGUUAUCAUGGUACCGAUGCUGUAU
101



AUCUGAAAGGUACAGUACUGUGAUAACUGAAGAAUGGU




GGU



 


miR-101-9
UGUCCUUUUUCGGUUAUCAUGGUACCGAUGCUGUAUAU
102



CUGAAAGGUACAGUACUGUGAUAACUGAAGAAUGGUG



 


miR-102-1
CUUCUGGAAGCUGGUUUCACAUGGUGGCUUAGAUUUUU
103



CCAUCUUUGUAUCUAGCACCAUUUGAAAUCAGUGUUUU




AGGAG



 


miR-102-7.1
CUUCAGGAAGCUGGUUUCAUAUGGUGGUUUAGAUUUAA
104


(miR-102-7.2)
AUAGUGAUUGUCUAGCACCAUUUGAAAUCAGUGUUCUU




GGGGG



 


miR-103-2
UUGUGCUUUCAGCUUCUUUACAGUGCUGCCUUGUAGCA
105



UUCAGGUCAAGCAACAUUGUACAGGGCUAUGAAAGAAC




CA



 


miR-103-1
UACUGCCCUCGGCUUCUUUACAGUGCUGCCUUGUUGCAU
106



AUGGAUCAAGCAGCAUUGUACAGGGCUAUGAAGGCAUU




G



 


miR-104-17
AAAUGUCAGACAGCCCAUCGACUGGUGUUGCCAUGAGA
107



UUCAACAGUCAACAUCAGUCUGAUAAGCUACCCGACAAG




G



 


miR-105-1
UGUGCAUCGUGGUCAAAUGCUCAGACUCCUGUGGUGGC
108



UGCUCAUGCACCACGGAUGUUUGAGCAUGUGCUACGGU




GUCUA



 


miR-105-2
UGUGCAUCGUGGUCAAAUGCUCAGACUCCUGUGGUGGC
109



UGCUUAUGCACCACGGAUGUUUGAGCAUGUGCUAUGGU




GUCUA



 


miR-106-a
CCUUGGCCAUGUAAAAGUGCUUACAGUGCAGGUAGCUU
110



UUUGAGAUCUACUGCAAUGUAAGCACUUCUUACAUUAC




CAUGG



 


miR-106-b
CCUGCCGGGGCUAAAGUGCUGACAGUGCAGAUAGUGGU
111



CCUCUCCGUGCUACCGCACUGUGGGUACUUGCUGCUCCA




GCAGG



 


miR-107
CUCUCUGCUUUCAGCUUCUUUACAGUGUUGCCUUGUGGC
112



AUGGAGUUCAAGCAGCAUUGUACAGGGCUAUCAAAGCA




CAGA



 


MIR-108-1-
ACACUGCAAGAACAAUAAGGAUUUUUAGGGGCAUUAUG
113


SMALL
ACUGAGUCAGAAAACACAGCUGCCCCUGAAAGUCCCUCA




UUUUUCUUGCUGU



 


MIR-108-2-
ACUGCAAGAGCAAUAAGGAUUUUUAGGGGCAUUAUGAU
114


SMALL
AGUGGAAUGGAAACACAUCUGCCCCCAAAAGUCCCUCAU




UUU



 


miR-122a-1
CCUUAGCAGAGCUGUGGAGUGUGACAAUGGUGUUUGUG
115



UCUAAACUAUCAAACGCCAUUAUCACACUAAAUAGCUAC




UGCUAGGC



 


miR-122a-2
AGCUGUGGAGUGUGACAAUGGUGUUUGUGUCCAAACUA
116



UCAAACGCCAUUAUCACACUAAAUAGCU



 


miR-123
ACAUUAUUACUUUUGGUACGCGCUGUGACACUUCAAAC
117



UCGUACCGUGAGUAAUAAUGCGC



 


miR-124a-1
AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAA
118



AUGUCCAUACAAUUAAGGCACGCGGUGAAUGCCAAGAA




UGGGGCUG



 


miR-124a-2
AUCAAGAUUAGAGGCUCUGCUCUCCGUGUUCACAGCGGA
119



CCUUGAUUUAAUGUCAUACAAUUAAGGCACGCGGUGAA




UGCCAAGAGCGGAGCCUACGGCUGCACUUGAAG



 


miR-124a-3
UGAGGGCCCCUCUGCGUGUUCACAGCGGACCUUGAUUUA
120



AUGUCUAUACAAUUAAGGCACGCGGUGAAUGCCAAGAG




AGGCGCCUCC



 


miR-124a
CUCUGCGUGUUCACAGCGGACCUUGAUUUAAUGUCUAU
121



ACAAUUAAGGCACGCGGUGAAUGCCAAGAG



 


miR-124b
CUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCAUAC
122



AAUUAAGGCACGCGGUGAAUGCCAAGAG



 


miR-125a-1
UGCCAGUCUCUAGGUCCCUGAGACCCUUUAACCUGUGAG
123



GACAUCCAGGGUCACAGGUGAGGUUCUUGGGAGCCUGG




CGUCUGGCC



 


miR-125a-2
GGUCCCUGAGACCCUUUAACCUGUGAGGACAUCCAGGGU
124



CACAGGUGAGGUUCUUGGGAGCCUGG



 


miR-125b-1
UGCGCUCCUCUCAGUCCCUGAGACCCUAACUUGUGAUGU
125



UUACCGUUUAAAUCCACGGGUUAGGCUCUUGGGAGCUG




CGAGUCGUGCU



 


miR-125b-2
ACCAGACUUUUCCUAGUCCCUGAGACCCUAACUUGUGAG
126



GUAUUUUAGUAACAUCACAAGUCAGGCUCUUGGGACCU




AGGCGGAGGGGA



 


miR-126-1
CGCUGGCGACGGGACAUUAUUACUUUUGGUACGCGCUG
127



UGACACUUCAAACUCGUACCGUGAGUAAUAAUGCGCCGU




CCACGGCA



 


miR-126-2
ACAUUAUUACUUUUGGUACGCGCUGUGACACUUCAAAC
128



UCGUACCGUGAGUAAUAAUGCGC



 


miR-127-1
UGUGAUCACUGUCUCCAGCCUGCUGAAGCUCAGAGGGCU
129



CUGAUUCAGAAAGAUCAUCGGAUCCGUCUGAGCUUGGC




UGGUCGGAAGUCUCAUCAUC



 


miR-127-2
CCAGCCUGCUGAAGCUCAGAGGGCUCUGAUUCAGAAAGA
130



UCAUCGGAUCCGUCUGAGCUUGGCUGGUCGG



 


miR-128a
UGAGCUGUUGGAUUCGGGGCCGUAGCACUGUCUGAGAG
131



GUUUACAUUUCUCACAGUGAACCGGUCUCUUUUUCAGCU




GCUUC



 


miR-128b
GCCCGGCAGCCACUGUGCAGUGGGAAGGGGGGCCGAUAC
132



ACUGUACGAGAGUGAGUAGCAGGUCUCACAGUGAACCG




GUCUCUUUCCCUACUGUGUCACACUCCUAAUGG



 


miR-128
GUUGGAUUCGGGGCCGUAGCACUGUCUGAGAGGUUUAC
133



AUUUCUCACAGUGAACCGGUCUCUUUUUCAGC



 


miR-129-1
UGGAUCUUUUUGCGGUCUGGGCUUGCUGUUCCUCUCAAC
134



AGUAGUCAGGAAGCCCUUACCCCAAAAAGUAUCUA



 


MIR-129-2
UGCCCUUCGCGAAUCUUUUUGCGGUCUGGGCUUGCUGUA
135



CAUAACUCAAUAGCCGGAAGCCCUUACCCCAAAAAGCAU




UUGCGGAGGGCG



 


miR-130a
UGCUGCUGGCCAGAGCUCUUUUCACAUUGUGCUACUGUC
136



UGCACCUGUCACUAGCAGUGCAAUGUUAAAAGGGCAUU




GGCCGUGUAGUG



 


miR-131-1
GCCAGGAGGCGGGGUUGGUUGUUAUCUUUGGUUAUCUA
137



GCUGUAUGAGUGGUGUGGAGUCUUCAUAAAGCUAGAUA




ACCGAAAGUAAAAAUAACCCCAUACACUGCGCAG



 


miR-131-3
CACGGCGCGGCAGCGGCACUGGCUAAGGGAGGCCCGUUU
138



CUCUCUUUGGUUAUCUAGCUGUAUGAGUGCCACAGAGCC




GUCAUAAAGCUAGAUAACCGAAAGUAGAAAUG



 


miR-131
GUUGUUAUCUUUGGUUAUCUAGCUGUAUGAGUGUAUUG
139



GUCUUCAUAAAGCUAGAUAACCGAAAGUAAAAAC



 


miR-132-1
CCGCCCCCGCGUCUCCAGGGCAACCGUGGCUUUCGAUUG
140



UUACUGUGGGAACUGGAGGUAACAGUCUACAGCCAUGG




UCGCCCCGCAGCACGCCCACGCGC



 


miR-132-2
GGGCAACCGUGGCUUUCGAUUGUUACUGUGGGAACUGG
141



AGGUAACAGUCUACAGCCAUGGUCGCCC



 


miR-133a-1
ACAAUGCUUUGCUAGAGCUGGUAAAAUGGAACCAAAUC
142



GCCUCUUCAAUGGAUUUGGUCCCCUUCAACCAGCUGUAG




CUAUGCAUUGA



 


miR-133a-2
GGGAGCCAAAUGCUUUGCUAGAGCUGGUAAAAUGGAAC
143



CAAAUCGACUGUCCAAUGGAUUUGGUCCCCUUCAACCAG




CUGUAGCUGUGCAUUGAUGGCGCCG



 


miR-133
GCUAGAGCUGGUAAAAUGGAACCAAAUCGCCUCUUCAA
144



UGGAUUUGGUCCCCUUCAACCAGCUGUAGC



 


miR-133b
CCUCAGAAGAAAGAUGCCCCCUGCUCUGGCUGGUCAAAC
145



GGAACCAAGUCCGUCUUCCUGAGAGGUUUGGUCCCCUUC




AACCAGCUACAGCAGGGCUGGCAAUGCCCAGUCCUUGGA




GA



 


MIR-133B-
GCCCCCUGCUCUGGCUGGUCAAACGGAACCAAGUCCGUC
146


SMALL
UUCCUGAGAGGUUUGGUCCCCUUCAACCAGCUACAGCAG




GG



 


miR-134-1
CAGGGUGUGUGACUGGUUGACCAGAGGGGCAUGCACUG
147



UGUUCACCCUGUGGGCCACCUAGUCACCAACCCUC



 


miR-134-2
AGGGUGUGUGACUGGUUGACCAGAGGGGCAUGCACUGU
148



GUUCACCCUGUGGGCCACCUAGUCACCAACCCU



 


miR-135a-1
AGGCCUCGCUGUUCUCUAUGGCUUUUUAUUCCUAUGUG
149



AUUCUACUGCUCACUCAUAUAGGGAUUGGAGCCGUGGC




GCACGGCGGGGACA



 


miR-135a-2
AGAUAAAUUCACUCUAGUGCUUUAUGGCUUUUUAUUCC
150


(miR-135-2)
UAUGUGAUAGUAAUAAAGUCUCAUGUAGGGAUGGAAGC




CAUGAAAUACAUUGUGAAAAAUCA



 


miR-135
CUAUGGCUUUUUAUUCCUAUGUGAUUCUACUGCUCACUC
151



AUAUAGGGAUUGGAGCCGUGG



 


miR-135b
CACUCUGCUGUGGCCUAUGGCUUUUCAUUCCUAUGUGAU
152



UGCUGUCCCAAACUCAUGUAGGGCUAAAAGCCAUGGGCU




ACAGUGAGGGGCGAGCUCC



 


miR-136-1
UGAGCCCUCGGAGGACUCCAUUUGUUUUGAUGAUGGAU
153



UCUUAUGCUCCAUCAUCGUCUCAAAUGAGUCUUCAGAGG




GUUCU



 


miR-136-2
GAGGACUCCAUUUGUUUUGAUGAUGGAUUCUUAUGCUC
154



CAUCAUCGUCUCAAAUGAGUCUUC



 


miR-137
CUUCGGUGACGGGUAUUCUUGGGUGGAUAAUACGGAUU
155



ACGUUGUUAUUGCUUAAGAAUACGCGUAGUCGAGG



 


miR-138-1
CCCUGGCAUGGUGUGGUGGGGCAGCUGGUGUUGUGAAU
156



CAGGCCGUUGCCAAUCAGAGAACGGCUACUUCACAACAC




CAGGGCCACACCACACUACAGG



 


miR-138-2
CGUUGCUGCAGCUGGUGUUGUGAAUCAGGCCGACGAGC
157



AGCGCAUCCUCUUACCCGGCUAUUUCACGACACCAGGGU




UGCAUCA



 


miR-138
CAGCUGGUGUUGUGAAUCAGGCCGACGAGCAGCGCAUCC
158



UCUUACCCGGCUAUUUCACGACACCAGGGUUG



 


miR-139
GUGUAUUCUACAGUGCACGUGUCUCCAGUGUGGCUCGG
159



AGGCUGGAGACGCGGCCCUGUUGGAGUAAC



 


miR-140
UGUGUCUCUCUCUGUGUCCUGCCAGUGGUUUUACCCUAU
160



GGUAGGUUACGUCAUGCUGUUCUACCACAGGGUAGAAC




CACGGACAGGAUACCGGGGCACC



 


miR-140as
UCCUGCCAGUGGUUUUACCCUAUGGUAGGUUACGUCAU
161



GCUGUUCUACCACAGGGUAGAACCACGGACAGGA



 


miR-140s
CCUGCCAGUGGUUUUACCCUAUGGUAGGUUACGUCAUGC
162



UGUUCUACCACAGGGUAGAACCACGGACAGG



 


miR-141-1
CGGCCGGCCCUGGGUCCAUCUUCCAGUACAGUGUUGGAU
163



GGUCUAAUUGUGAAGCUCCUAACACUGUCUGGUAAAGA




UGGCUCCCGGGUGGGUUC



 


miR-141-2
GGGUCCAUCUUCCAGUACAGUGUUGGAUGGUCUAAUUG
164



UGAAGCUCCUAACACUGUCUGGUAAAGAUGGCCC



 


miR-142
ACCCAUAAAGUAGAAAGCACUACUAACAGCACUGGAGG
165



GUGUAGUGUUUCCUACUUUAUGGAUG



 


miR-143-1
GCGCAGCGCCCUGUCUCCCAGCCUGAGGUGCAGUGCUGC
166



AUCUCUGGUCAGUUGGGAGUCUGAGAUGAAGCACUGUA




GCUCAGGAAGAGAGAAGUUGUUCUGCAGC



 


miR-143-2
CCUGAGGUGCAGUGCUGCAUCUCUGGUCAGUUGGGAGU
167



CUGAGAUGAAGCACUGUAGCUCAGG



 


miR-144-1
UGGGGCCCUGGCUGGGAUAUCAUCAUAUACUGUAAGUU
168



UGC GAUGAGACACUACAGUAUAGAUGAUGUACUAGUCC




GGGCACCCCC



 


miR-144-2
GGCUGGGAUAUCAUCAUAUACUGUAAGUUUGCGAUGAG
169



ACACUACAGUAUAGAUGAUGUACUAGUC



 


miR-145-1
CACCUUGUCCUCACGGUCCAGUUUUCCCAGGAAUCCCUU
170



AGAUGCUAAGAUGGGGAUUCCUGGAAAUACUGUUCUUG




AGGUCAUGGUU



 


miR-145-2
CUCACGGUCCAGUUUUCCCAGGAAUCCCUUAGAUGCUAA
171



GAUGGGGAUUCCUGGAAAUACUGUUCUUGAG



 


miR-146-1
CCGAUGUGUAUCCUCAGCUUUGAGAACUGAAUUCCAUG
172



GGUUGUGUCAGUGUCAGACCUCUGAAAUUCAGUUCUUC




AGCUGGGAUAUCUCUGUCAUCGU



 


miR-146-2
AGCUUUGAGAACUGAAUUCCAUGGGUUGUGUCAGUGUC
173



AGACCUGUGAAAUUCAGUUCUUCAGCU



 


miR-147
AAUCUAAAGACAACAUUUCUGCACACACACCAGACUAUG
174



GAAGCCAGUGUGUGGAAAUGCUUCUGCUAGAUU



 


miR-148a
GAGGCAAAGUUCUGAGACACUCCGACUCUGAGUAUGAU
175


(miR-148)
AGAAGUCAGUGCACUACAGAACUUUGUCUC



 


miR-148b
CAAGCACGAUUAGCAUUUGAGGUGAAGUUCUGUUAUAC
176



ACUCAGGCUGUGGCUCUCUGAAAGUCAGUGCAUCACAGA




ACUUUGUCUCGAAAGCUUUCUA



 


MIR-148B-
AAGCACGAUUAGCAUUUGAGGUGAAGUUCUGUUAUACA
177


SMALL
CUCAGGCUGUGGCUCUCUGAAAGUCAGUGCAU



 


miR-149-1
GCCGGCGCCCGAGCUCUGGCUCCGUGUCUUCACUCCCGU
178



GCUUGUCCGAGGAGGGAGGGAGGGACGGGGGCUGUGCU




GGGGCAGCUGGA



 


miR-149-2
GCUCUGGCUCCGUGUCUUCACUCCCGUGCUUGUCCGAGG
179



AGGGAGGGAGGGAC



 


miR-150-1
CUCCCCAUGGCCCUGUCUCCCAACCCUUGUACCAGUGCU
180



GGGCUCAGACCCUGGUACAGGCCUGGGGGACAGGGACCU




GGGGAC



 


miR-150-2
CCCUGUCUCCCAACCCUUGUACCAGUGCUGGGCUCAGAC
181



CCUGGUACAGGCCUGGGGGACAGGG



 


miR-151
UUUCCUGCCCUCGAGGAGCUCACAGUCUAGUAUGUCUCA
182



UCCCCUACUAGACUGAAGCUCCUUGAGGACAGG



 


MIR-151-2
CCUGUCCUCAAGGAGCUUCAGUCUAGUAGGGGAUGAGA
183



CAUACUAGACUGUGAGCUCCUCGAGGGCAGG



 


miR-152-1
UGUCCCCCCCGGCCCAGGUUCUGUGAUACACUCCGACUC
184



GGGCUCUGGAGCAGUCAGUGCAUGACAGAACUUGGGCCC




GGAAGGACC



 


miR-152-2
GGCCCAGGUUCUGUGAUACACUCCGACUCGGGCUCUGGA
185



GCAGUCAGUGCAUGACAGAACUUGGGCCCCGG



 


miR-153-1-1
CUCACAGCUGCCAGUGUCAUUUUUGUGAUCUGCAGCUAG
186



UAUUCUCACUCCAGUUGCAUAGUCACAAAAGUGAUCAU




UGGCAGGUGUGGC



 


miR-153-1-2
UCUCUCUCUCCCUCACAGCUGCCAGUGUCAUUGUCACAA
187



AAGUGAUCAUUGGCAGGUGUGGCUGCUGCAUG



 


miR-153-2-1
AGCGGUGGCCAGUGUCAUUUUUGUGAUGUUGCAGCUAG
188



UAAUAUGAGCCCAGUUGCAUAGUCACAAAAGUGAUCAU




UGGAAACUGUG



 


miR-153-2-2
CAGUGUCAUUUUUGUGAUGUUGCAGCUAGUAAUAUGAG
189



CCCAGUUGCAUAGUCACAAAAGUGAUCAUUG



 


miR-154-1
GUGGUACUUGAAGAUAGGUUAUCCGUGUUGCCUUCGCU
190



UUAUUUGUGACGAAUCAUACACGGUUGACCUAUUUUUC




AGUACCAA



 


miR-154-2
GAAGAUAGGUUAUCCGUGUUGCCUUCGCUUUAUUUGUG
191



ACGAAUCAUACACGGUUGACCUAUUUUU



 


miR-155
CUGUUAAUGCUAAUCGUGAUAGGGGUUUUUGCCUCCAA
192



CUGACUCCUACAUAUUAGCAUUAACAG



 


MIR-156 =
CCUAACACUGUCUGGUAAAGAUGGCUCCCGGGUGGGUUC
193


MIR-
UCUCGGCAGUAACCUUCAGGGAGCCCUGAAGACCAUGGA



157 = OVER-
GGAC



LAP MIR-141




 


MIR-158-
GCCGAGACCGAGUGCACAGGGCUCUGACCUAUGAAUUGA
194


SMALL =
CAGCCAGUGCUCUCGUCUCCCCUCUGGCUGCCAAUUCCA



MIR-192
UAGGUCACAGGUAUGUUCGCCUCAAUGCCAGC



 


MIR-159-1-
UCCCGCCCCCUGUAACAGCAACUCCAUGUGGAAGUGCCC
195


SMALL
ACUGGUUCCAGUGGGGCUGCUGUUAUCUGGGGCGAGGG




CCA



 


MIR-161-
AAAGCUGGGUUGAGAGGGCGAAAAAGGAUGAGGUGACU
196


SMALL
GGUCUGGGCUACGCUAUGCUGCGGCGCUCGGG



 


MIR-163-1B-
CAUUGGCCUCCUAAGCCAGGGAUUGUGGGUUCGAGUCCC
197


SMALL
ACCCGGGGUAAAGAAAGGCCGAAUU



 


MIR-163-3-
CCUAAGCCAGGGAUUGUGGGUUCGAGUCCCACCUGGGGU
198


SMALL
AGAGGUGAAAGUUCCUUUUACGGAAUUUUUU



 


miR-162
CAAUGUCAGCAGUGCCUUAGCAGCACGUAAAUAUUGGC
199



GUUAAGAUUCUAAAAUUAUCUCCAGUAUUAACUGUGCU




GCUGAAGUAAGGUUGACCAUACUCUACAGUUG



 


MIR-175-
GGGCUUUCAAGUCACUAGUGGUUCCGUUUAGUAGAUGA
200


SMALL = MIR-
UUGUGCAUUGUUUCAAAAUGGUGCCCUAGUGACUACAA



224
AGCCC



 


MIR-177-
ACGCAAGUGUCCUAAGGUGAGCUCAGGGAGCACAGAAA
201


SMALL
CCUCCAGUGGAACAGAAGGGCAAAAGCUCAUU



 


MIR-180-
CAUGUGUCACUUUCAGGUGGAGUUUCAAGAGUCCCUUCC
202


SMALL
UGGUUCACCGUCUCCUUUGCUCUUCCACAAC



 


miR-181a
AGAAGGGCUAUCAGGCCAGCCUUCAGAGGACUCCAAGGA
203



ACAUUCAACGCUGUCGGUGAGUUUGGGAUUUGAAAAAA




CCACUGACCGUUGACUGUACCUUGGGGUCCUUA



 


miR-181b-1
CCUGUGCAGAGAUUAUUUUUUAAAAGGUCACAAUCAAC
204



AUUCAUUGCUGUCGGUGGGUUGAACUGUGUGGACAAGC




UCACUGAACAAUGAAUGCAACUGUGGCCCCGCUU



 


miR-181b-2
CUGAUGGCUGCACUCAACAUUCAUUGCUGUCGGUGGGU
205



UUGAGUCUGAAUCAACUCACUGAUCAAUGAAUGCAAAC




UGCGGACCAAACA



 


miR-181c
CGGAAAAUUUGCCAAGGGUUUGGGGGAACAUUCAACCU
206



GUCGGUGAGUUUGGGCAGCUCAGGCAAACCAUCGACCGU




UGAGUGGACCCUGAGGCCUGGAAUUGCCAUCCU



 


miR-182-as
GAGCUGCUUGCCUCCCCCCGUUUUUGGCAAUGGUAGAAC
207



UCACACUGGUGAGGUAACAGGAUCCGGUGGUUCUAGAC




UUGCCAACUAUGGGGCGAGGACUCAGCCGGCAC



 


miR-182
UUUUUGGCAAUGGUAGAACUCACACUGGUGAGGUAACA
208



GGAUCCGGUGGUUCUAGACUUGCCAACUAUGG



 


miR-183
CCGCAGAGUGUGACUCCUGUUCUGUGUAUGGCACUGGU
209



AGAAUUCACUGUGAACAGUCUCAGUCAGUGAAUUACCG




AAGGGCCAUAAACAGAGCAGAGACAGAUCCACGA



 


miR-184-1
CCAGUCACGUCCCCUUAUCACUUUUCCAGCCCAGCUUUG
210



UGACUGUAAGUGUUGGACGGAGAACUGAUAAGGGUAGG




UGAUUGA



 


miR-184-2
CCUUAUCACUUUUCCAGCCCAGCUUUGUGACUGUAAGUG
211



UUGGACGGAGAACUGAUAAGGGUAGG



 


miR-185-1
AGGGGGCGAGGGAUUGGAGAGAAAGGCAGUUCCUGAUG
212



GUCCCCUCCCCAGGGGCUGGCUUUCCUCUGGUCCUUCCC




UCCCA



 


miR-185-2
AGGGAUUGGAGAGAAAGGCAGUUCCUGAUGGUCCCCUC
213



CCCAGGGGCUGGCUUUCCUCUGGUCCUU



 


miR-186-1
UGCUUGUAACUUUCCAAAGAAUUCUCCUUUUGGGCUUU
214



CUGGUUUUAUUUUAAGCCCAAAGGUGAAUUUUUUGGGA




AGUUUGAGCU



 


miR-186-2
ACUUUCCAAAGAAUUCUCCUUUUGGGCUUUCUGGUUUU
215



AUUUUAAGCCCAAAGGUGAAUUUUUUGGGAAGU



 


miR-187
GGUCGGGCUCACCAUGACACAGUGUGAGACUCGGGCUAC
216



AACACAGGACCCGGGGCGCUGCUCUGACCCCUCGUGUCU




UGUGUUGCAGCCGGAGGGACGCAGGUCCGCA



 


miR-188-1
UGCUCCCUCUCUCACAUCCCUUGCAUGGUGGAGGGUGAG
217



CUUUCUGAAAACCCCUCCCACAUGCAGGGUUUGCAGGAU




GGCGAGCC



 


miR-188-2
UCUCACAUCCCUUGCAUGGUGGAGGGUGAGCUUUCUGA
218



AAACCCCUCCCACAUGCAGGGUUUGCAGGA



 


miR-189-1
CUGUCGAUUGGACCCGCCCUCCGGUGCCUACUGAGCUGA
219



UAUCAGUUCUCAUUUUACACACUGGCUCAGUUCAGCAGG




AACAGGAGUCGAGCCCUUGAGCAA



 


miR-189-2
CUCCGGUGCCUACUGAGCUGAUAUCAGUUCUCAUUUUAC
220



ACACUGGCUCAGUUCAGCAGGAACAGGAG



 


miR-190-1
UGCAGGCCUCUGUGUGAUAUGUUUGAUAUAUUAGGUUG
221



UUAUUUAAUCCAACUAUAUAUCAAACAUAUUCCUACAG




UGUCUUGCC



 


miR-190-2
CUGUGUGAUAUGUUUGAUAUAUUAGGUUGUUAUUUAAU
222



CCAACUAUAUAUCAAACAUAUUCCUACAG



 


miR-191-1
CGGCUGGACAGCGGGCAACGGAAUCCCAAAAGCAGCUGU
223



UGUCUCCAGAGCAUUCCAGCUGCGCUUGGAUUUCGUCCC




CUGCUCUCCUGCCU



 


miR-191-2
AGCGGGCAACGGAAUCCCAAAAGCAGCUGUUGUCUCCAG
224



AGCAUUCCAGCUGCGCUUGGAUUUCGUCCCCUGCU



 


miR-192-2/3
CCGAGACCGAGUGCACAGGGCUCUGACCUAUGAAUUGAC
225



AGCCAGUGCUCUCGUCUCCCCUCUGGCUGCCAAUUCCAU




AGGUCACAGGUAUGUUCGCCUCAAUGCCAG



 


miR-192
GCCGAGACCGAGUGCACAGGGCUCUGACCUAUGAAUUGA
226



CAGCCAGUGCUCUCGUCUCCCCUCUGGCUGCCAAUUCCA




UAGGUCACAGGUAUGUUCGCCUCAAUGCCAGC



 


miR-193-1
CGAGGAUGGGAGCUGAGGGCUGGGUCUUUGCGGGCGAG
227



AUGAGGGUGUCGGAUCAACUGGCCUACAAAGUCCCAGU




UCUCGGCCCCCG



 


miR-193-2
GCUGGGUCUUUGCGGGCGAGAUGAGGGUGUCGGAUCAA
228



CUGGCCUACAAAGUCCCAGU



 


miR-194-1
AUGGUGUUAUCAAGUGUAACAGCAACUCCAUGUGGACU
229



GUGUACCAAUUUCCAGUGGAGAUGCUGUUACUUUUGAU




GGUUACCAA



 


miR-194-2
GUGUAACAGCAACUCCAUGUGGACUGUGUACCAAUUUCC
230



AGUGGAGAUGCUGUUACUUUUGAU



 


miR-195-1
AGCUUCCCUGGCUCUAGCAGCACAGAAAUAUUGGCACAG
231



GGAAGCGAGUCUGCCAAUAUUGGCUGUGCUGCUCCAGGC




AGGGUGGUG



 


miR-195-2
UAGCAGCACAGAAAUAUUGGCACAGGGAAGCGAGUCUG
232



CCAAUAUUGGCUGUGCUGCU



 


miR-196-1
CUAGAGCUUGAAUUGGAACUGCUGAGUGAAUUAGGUAG
233



UUUCAUGUUGUUGGGCCUGGGUUUCUGAACACAACAAC




AUUAAACCACCCGAUUCACGGCAGUUACUGCUCC



 


miR-196a-1
GUGAAUUAGGUAGUUUCAUGUUGUUGGGCCUGGGUUUC
234



UGAACACAACAACAUUAAACCACCCGAUUCAC



 


miR-196a-2
UGCUCGCUCAGCUGAUCUGUGGCUUAGGUAGUUUCAUG
235


(miR-196-2)
UUGUUGGGAUUGAGUUUUGAACUCGGCAACAAGAAACU




GCCUGAGUUACAUCAGUCGGUUUUCGUCGAGGGC



 


miR-196
GUGAAUUAGGUAGUUUCAUGUUGUUGGGCCUGGGUUUC
236



UGAACACAACAACAUUAAACCACCCGAUUCAC



 


miR-196b
ACUGGUCGGUGAUUUAGGUAGUUUCCUGUUGUUGGGAU
237



CCACCUUUCUCUCGACAGCACGACACUGCCUUCAUUACU




UCAGUUG



 


miR-197
GGCUGUGCCGGGUAGAGAGGGCAGUGGGAGGUAAGAGC
238



UCUUCACCCUUCACCACCUUCUCCACCCAGCAUGGCC



 


MIR-197-2
GUGCAUGUGUAUGUAUGUGUGCAUGUGCAUGUGUAUGU
239



GUAUGAGUGCAUGCGUGUGUGC



 


miR-198
UCAUUGGUCCAGAGGGGAGAUAGGUUCCUGUGAUUUUU
240



CCUUCUUCUCUAUAGAAUAAAUGA



 


miR-199a-1
GCCAACCCAGUGUUCAGACUACCUGUUCAGGAGGCUCUC
241



AAUGUGUACAGUAGUCUGCACAUUGGUUAGGC



 


miR-199a-2
AGGAAGCUUCUGGAGAUCCUGCUCCGUCGCCCCAGUGUU
242



CAGACUACCUGUUCAGGACAAUGCCGUUGUACAGUAGUC




UGCACAUUGGUUAGACUGGGCAAGGGAGAGCA



 


miR-199b
CCAGAGGACACCUCCACUCCGUCUACCCAGUGUUUAGAC
243



UAUCUGUUCAGGACUCCCAAAUUGUACAGUAGUCUGCAC




AUUGGUUAGGCUGGGCUGGGUUAGACCCUCGG



 


miR-199s
GCCAACCCAGUGUUCAGACUACCUGUUCAGGAGGCUCUC
244



AAUGUGUACAGUAGUCUGCACAUUGGUUAGGC



 


miR-200a
GCCGUGGCCAUCUUACUGGGCAGCAUUGGAUGGAGUCA
245



GGUCUCUAAUACUGCCUGGUAAUGAUGACGGC



 


miR-200b
CCAGCUCGGGCAGCCGUGGCCAUCUUACUGGGCAGCAUU
246



GGAUGGAGUCAGGUCUCUAAUACUGCCUGGUAAUGAUG




ACGGCGGAGCCCUGCACG



 


miR-200c
CCCUCGUCUUACCCAGCAGUGUUUGGGUGCGGUUGGGAG
247



UCUCUAAUACUGCCGGGUAAUGAUGGAGG



 


miR-202
GUUCCUUUUUCCUAUGCAUAUACUUCUUUGAGGAUCUG
248



GCCUAAAGAGGUAUAGGGCAUGGGAAGAUGGAGC



 


miR-203
GUGUUGGGGACUCGCGCGCUGGGUCCAGUGGUUCUUAA
249



CAGUUCAACAGUUCUGUAGCGCAAUUGUGAAAUGUUUA




GGACCACUAGACCCGGCGGGCGCGGCGACAGCGA



 


miR-204
GGCUACAGUCUUUCUUCAUGUGACUCGUGGACUUCCCUU
250



UGUCAUCCUAUGCCUGAGAAUAUAUGAAGGAGGCUGGG




AAGGCAAAGGGACGUUCAAUUGUCAUCACUGGC



 


miR-205
AAAGAUCCUCAGACAAUCCAUGUGCUUCUCUUGUCCUUC
251



AUUCCACCGGAGUCUGUCUCAUACCCAACCAGAUUUCAG




UGGAGUGAAGUUCAGGAGGCAUGGAGCUGACA



 


miR-206-1
UGCUUCCCGAGGCCACAUGCUUCUUUAUAUCCCCAUAUG
252



GAUUACUUUGCUAUGGAAUGUAAGGAAGUGUGUGGUUU




CGGCAAGUG



 


miR-206-2
AGGCCACAUGCUUCUUUAUAUCCCCAUAUGGAUUACUUU
253



GCUAUGGAAUGUAAGGAAGUGUGUGGUUUU



 


miR-208
UGACGGGCGAGCUUUUGGCCCGGGUUAUACCUGAUGCUC
254



ACGUAUAAGACGAGCAAAAAGCUUGUUGGUCA



 


miR-210
ACCCGGCAGUGCCUCCAGGCGCAGGGCAGCCCCUGCCCA
255



CCGCACACUGCGCUGCCCCAGACCCACUGUGCGUGUGAC




AGCGGCUGAUCUGUGCCUGGGCAGCGCGACCC



 


miR-211
UCACCUGGCCAUGUGACUUGUGGGCUUCCCUUUGUCAUC
256



CUUCGCCUAGGGCUCUGAGCAGGGCAGGGACAGCAAAGG




GGUGCUCAGUUGUCACUUCCCACAGCACGGAG



 


miR-212
CGGGGCACCCCGCCCGGACAGCGCGCCGGCACCUUGGCU
257



CUAGACUGCUUACUGCCCGGGCCGCCCUCAGUAACAGUC




UCCAGUCACGGCCACCGACGCCUGGCCCCGCC



 


miR-213-2
CCUGUGCAGAGAUUAUUUUUUAAAAGGUCACAAUCAAC
258



AUUCAUUGCUGUCGGUGGGUUGAACUGUGUGGACAAGC




UCACUGAACAAUGAAUGCAACUGUGGCCCCGCUU



 


miR-213
GAGUUUUGAGGUUGCUUCAGUGAACAUUCAACGCUGUC
259



GGUGAGUUUGGAAUUAAAAUCAAAACCAUCGACCGUUG




AUUGUACCCUAUGGCUAACCAUCAUCUACUCC



 


miR-214
GGCCUGGCUGGACAGAGUUGUCAUGUGUCUGCCUGUCU
260



ACACUUGCUGUGCAGAACAUCCGCUCACCUGUACAGCAG




GCACAGACAGGCAGUCACAUGACAACCCAGCCU



 


miR-215
AUCAUUCAGAAAUGGUAUACAGGAAAAUGACCUAUGAA
261



UUGACAGACAAUAUAGCUGAGUUUGUCUGUCAUUUCUU




UAGGCCAAUAUUCUGUAUGACUGUGCUACUUCAA



 


miR-216
GAUGGCUGUGAGUUGGCUUAAUCUCAGCUGGCAACUGU
262



GAGAUGUUCAUACAAUCCCUCACAGUGGUCUCUGGGAU




UAUGCUAAACAGAGCAAUUUCCUAGCCCUCACGA



 


miR-217
AGUAUAAUUAUUACAUAGUUUUUGAUGUCGCAGAUACU
263



GCAUCAGGAACUGAUUGGAUAAGAAUCAGUCACCAUCA




GUUCCUAAUGCAUUGCCUUCAGCAUCUAAACAAG



 


miR-218-1
GUGAUAAUGUAGCGAGAUUUUCUGUUGUGCUUGAUCUA
264



ACCAUGUGGUUGCGAGGUAUGAGUAAAACAUGGUUCCG




UCAAGCACCAUGGAACGUCACGCAGCUUUCUACA



 


miR-218-2
GACCAGUCGCUGCGGGGCUUUCCUUUGUGCUUGAUCUAA
265



CCAUGUGGUGGAACGAUGGAAACGGAACAUGGUUCUGU




CAAGCACCGCGGAAAGCACCGUGCUCUCCUGCA



 


miR-219
CCGCCCCGGGCCGCGGCUCCUGAUUGUCCAAACGCAAUU
266



CUCGAGUCUAUGGCUCCGGCCGAGAGUUGAGUCUGGACG




UCCCGAGCCGCCGCCCCCAAACCUCGAGCGGG



 


miR-219-1
CCGCCCCGGGCCGCGGCUCCUGAUUGUCCAAACGCAAUU
267



CUCGAGUCUAUGGCUCCGGCCGAGAGUUGAGUCUGGACG




UCCCGAGCCGCCGCCCCCAAACCUCGAGCGGG



 


miR-219-2
ACUCAGGGGCUUCGCCACUGAUUGUCCAAACGCAAUUCU
268



UGUACGAGUCUGCGGCCAACCGAGAAUUGUGGCUGGAC




AUCUGUGGCUGAGCUCCGGG



 


miR-220
GACAGUGUGGCAUUGUAGGGCUCCACACCGUAUCUGACA
269



CUUUGGGCGAGGGCACCAUGCUGAAGGUGUUCAUGAUG




CGGUCUGGGAACUCCUCACGGAUCUUACUGAUG



 


miR-221
UGAACAUCCAGGUCUGGGGCAUGAACCUGGCAUACAAU
270



GUAGAUUUCUGUGUUCGUUAGGCAACAGCUACAUUGUC




UGCUGGGUUUCAGGCUACCUGGAAACAUGUUCUC



 


miR-222
GCUGCUGGAAGGUGUAGGUACCCUCAAUGGCUCAGUAG
271



CCAGUGUAGAUCCUGUCUUUCGUAAUCAGCAGCUACAUC




UGGCUACUGGGUCUCUGAUGGCAUCUUCUAGCU



 


miR-223
CCUGGCCUCCUGCAGUGCCACGCUCCGUGUAUUUGACAA
272



GCUGAGUUGGACACUCCAUGUGGUAGAGUGUCAGUUUG




UCAAAUACCCCAAGUGCGGCACAUGCUUACCAG



 


miR-224
GGGCUUUCAAGUCACUAGUGGUUCCGUUUAGUAGAUGA
273



UUGUGCAUUGUUUCAAAAUGGUGCCCUAGUGACUACAA




AGCCC



 


MIR-294-1
CAAUCUUCCUUUAUCAUGGUAUUGAUUUUUCAGUGCUU
274


(CHR16)
CCCUUUUGUGUGAGAGAAGAUA



 


miR-296
AGGACCCUUCCAGAGGGCCCCCCCUCAAUCCUGUUGUGC
275



CUAAUUCAGAGGGUUGGGUGGAGGCUCUCCUGAAGGGC




UCU



 


miR-299
AAGAAAUGGUUUACCGUCCCACAUACAUUUUGAAUAUG
276



UAUGUGGGAUGGUAAACCGCUUCUU



 


miR-301
ACUGCUAACGAAUGCUCUGACUUUAUUGCACUACUGUAC
277



UUUACAGCUAGCAGUGCAAUAGUAUUGUCAAAGCAUCU




GAAAGCAGG



 


miR-302a
CCACCACUUAAACGUGGAUGUACUUGCUUUGAAACUAA
278



AGAAGUAAGUGCUUCCAUGUUUUGGUGAUGG



 


miR-302b
GCUCCCUUCAACUUUAACAUGGAAGUGCUUUCUGUGACU
279



UUAAAAGUAAGUGCUUCCAUGUUUUAGUAGGAGU



 


miR-302c
CCUUUGCUUUAACAUGGGGGUACCUGCUGUGUGAAACA
280



AAAGUAAGUGCUUCCAUGUUUCAGUGGAGG



 


miR-302d
CCUCUACUUUAACAUGGAGGCACUUGCUGUGACAUGACA
281



AAAAUAAGUGCUUCCAUGUUUGAGUGUGG



 


miR-320
GCUUCGCUCCCCUCCGCCUUCUCUUCCCGGUUCUUCCCG
282



GAGUCGGGAAAAGCUGGGUUGAGAGGGCGAAAAAGGAU




GAGGU



 


miR-321
UUGGCCUCCUAAGCCAGGGAUUGUGGGUUCGAGUCCCAC
283



CCGGGGUAAAGAAAGGCCGA



 


miR-323
UUGGUACUUGGAGAGAGGUGGUCCGUGGCGCGUUCGCU
284



UUAUUUAUGGCGCACAUUACACGGUCGACCUCUUUGCAG




UAUCUAAUC



 


miR-324
CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUA
285



AAGCUGGAGACCCACUGCCCCAGGUGCUGCUGGGGGUUG




UAGUC



 


miR-325
AUACAGUGCUUGGUUCCUAGUAGGUGUCCAGUAAGUGU
286



UUGUGACAUAAUUUGUUUAUUGAGGACCUCCUAUCAAU




CAAGCACUGUGCUAGGCUCUGG



 


miR-326
CUCAUCUGUCUGUUGGGCUGGAGGCAGGGCCUUUGUGA
287



AGGCGGGUGGUGCUCAGAUCGCCUCUGGGCCCUUCCUCC




AGCCCCGAGGCGGAUUCA



 


miR-328
UGGAGUGGGGGGGCAGGAGGGGCUCAGGGAGAAAGUGC
288



AUACAGCCCCUGGCCCUCUCUGCCCUUCCGUCCCCUG



 


miR-330
CUUUGGCGAUCACUGCCUCUCUGGGCCUGUGUCUUAGGC
289



UCUGCAAGAUCAACCGAGCAAAGCACACGGCCUGCAGAG




AGGCAGCGCUCUGCCC



 


miR-331
GAGUUUGGUUUUGUUUGGGUUUGUUCUAGGUAUGGUCC
290



CAGGGAUCCCAGAUCAAACCAGGCCCCUGGGCCUAUCCU




AGAACCAACCUAAGCUC



 


miR-335
UGUUUUGAGCGGGGGUCAAGAGCAAUAACGAAAAAUGU
291



UUGUCAUAAACCGUUUUUCAUUAUUGCUCCUGACCUCCU




CUCAUUUGCUAUAUUCA



 


miR-337
GUAGUCAGUAGUUGGGGGGUGGGAACGGCUUCAUACAG
292



GAGUUGAUGCACAGUUAUCCAGCUCCUAUAUGAUGCCU




UUCUUCAUCCCCUUCAA



 


miR-338
UCUCCAACAAUAUCCUGGUGCUGAGUGAUGACUCAGGCG
293



ACUCCAGCAUCAGUGAUUUUGUUGAAGA



 


miR-339
CGGGGCGGCCGCUCUCCCUGUCCUCCAGGAGCUCACGUG
294



UGCCUGCCUGUGAGCGCCUCGACGACAGAGCCGGCGCCU




GCCCCAGUGUCUGCGC



 


miR-340
UUGUACCUGGUGUGAUUAUAAAGCAAUGAGACUGAUUG
295



UCAUAUGUCGUUUGUGGGAUCCGUCUCAGUUACUUUAU




AGCCAUACCUGGUAUCUUA



 


miR-342
GAAACUGGGCUCAAGGUGAGGGGUGCUAUCUGUGAUUG
296



AGGGACAUGGUUAAUGGAAUUGUCUCACACAGAAAUCG




CACCCGUCACCUUGGCCUACUUA



 


miR-345
ACCCAAACCCUAGGUCUGCUGACUCCUAGUCCAGGGCUC
297



GUGAUGGCUGGUGGGCCCUGAACGAGGGGUCUGGAGGC




CUGGGUUUGAAUAUCGACAGC



 


miR-346
GUCUGUCUGCCCGCAUGCCUGCCUCUCUGUUGCUCUGAA
298



GGAGGCAGGGGCUGGGCCUGCAGCUGCCUGGGCAGAGCG




GCUCCUGC



 


miR-367
CCAUUACUGUUGCUAAUAUGCAACUCUGUUGAAUAUAA
299



AUUGGAAUUGCACUUUAGCAAUGGUGAUGG



 


miR-368
AAAAGGUGGAUAUUCCUUCUAUGUUUAUGUUAUUUAUG
300



GUUAAACAUAGAGGAAAUUCCACGUUUU



 


miR-369
UUGAAGGGAGAUCGACCGUGUUAUAUUCGCUUUAUUGA
301



CUUCGAAUAAUACAUGGUUGAUCUUUUCUCAG



 


miR-370
AGACAGAGAAGCCAGGUCACGUCUCUGCAGUUACACAGC
302



UCACGAGUGCCUGCUGGGGUGGAACCUGGUCUGUCU



 


miR-371
GUGGCACUCAAACUGUGGGGGCACUUUCUGCUCUCUGGU
303



GAAAGUGCCGCCAUCUUUUGAGUGUUAC



 


miR-372
GUGGGCCUCAAAUGUGGAGCACUAUUCUGAUGUCCAAG
304



UGGAAAGUGCUGCGACAUUUGAGCGUCAC



 


miR-373
GGGAUACUCAAAAUGGGGGCGCUUUCCUUUUUGUCUGU
305



ACUGGGAAGUGCUUCGAUUUUGGGGUGUCCC



 


miR-374
UACAUCGGCCAUUAUAAUACAACCUGAUAAGUGUUAUA
306



GCACUUAUCAGAUUGUAUUGUAAUUGUCUGUGUA



 


mir-hes1
AUGGAGCUGCUCACCCUGUGGGCCUCAAAUGUGGAGGA
307



ACUAUUCUGAUGUCCAAGUGGAAAGUGCUGCGACAUUU




GAGCGUCACCGGUGACGCCCAUAUCA



 


mir-hes2
GCAUCCCCUCAGCCUGUGGCACUCAAACUGUGGGGGCAC
308



UUUCUGCUCUCUGGUGAAAGUGCCGCCAUCUUUUGAGU




GUUACCGCUUGAGAAGACUCAACC



 


mir-hes3
CGAGGAGCUCAUACUGGGAUACUCAAAAUGGGGGCGCU
309



UUCCUUUUUGUCUGUUACUGGGAAGUGCUUCGAUUUUG




GGGUGUCCCUGUUUGAGUAGGGCAUC





*An underlined sequence within a precursor sequence corresponds to a mature processed miR transcript (see Table 1b). Some precursor sequences have two underlined sequences denoting two different mature miRs that are derived from the same precursor. All sequences are human.













TABLE 1b







Human Mature microRNA Sequences.










Mature miRNA
Mature miRNA Sequence
SEQ ID
Corresponding precursor


Name
(5′ to 3′)
NO.
microRNA(s); see Table 1a





let-7a
UGAGGUAGUAGGUUGUA
310
let-7a-1; let-7a-2; let-7a-3;



UAGUU

let-7a-4


 


let-7b
UGAGGUAGUAGGUUGUG
311
let-7b



UGGUU




 


let-7c
UGAGGUAGUAGGUUGUA
312
let-7c



UGGUU




 


let-7d
AGAGGUAGUAGGUUGCA
313
let-7d; let-7d-v1



UAGU




 


let-7e
UGAGGUAGGAGGUUGUA
314
let-7e



UAGU




 


let-7f
UGAGGUAGUAGAUUGUA
315
let-7f-1; let-7f-2-1;



UAGUU

let-7f-2-2


 


let-7g
UGAGGUAGUAGUUUGUA
316
let-7g



CAGU




 


let-7i
UGAGGUAGUAGUUUGUG
317
let-7i



CU




 


miR-1
UGGAAUGUAAAGAAGUA
318
miR-1b; miR-1b-1;



UGUA

miR-1b-2


 


miR-7
UGGAAGACUAGUGAUUU
319
miR-7-1; miR-7-1a;



UGUU

miR-7-2; miR-7-3


 


miR-9
UCUUUGGUUAUCUAGCU
320
miR-9-1; miR-9-2;



GUAUGA

miR-9-3


 


miR-9*
UAAAGCUAGAUAACCGA
321
miR-9-1; miR-9-2;



AAGU

miR-9-3


 


miR-10a
UACCCUGUAGAUCCGAA
322
miR-10a



UUUGUG




 


miR-10b
UACCCUGUAGAACCGAA
323
miR-10b



UUUGU




 


miR-15a
UAGCAGCACAUAAUGGU
324
miR-15a; miR-15a-2



UUGUG




 


miR-15b
UAGCAGCACAUCAUGGU
325
miR-15b



UUACA




 


miR-16
UAGCAGCACGUAAAUAU
326
miR-16-1; miR-16-2;



UGGCG

miR-16-13


 


miR-17-5p
CAAAGUGCUUACAGUGC
327
miR-17



AGGUAGU




 


miR-17-3p
ACUGCAGUGAAGGCACU
328
miR-17



UGU




 


miR-18
UAAGGUGCAUCUAGUGC
329
miR-18; miR-18-13



AGAUA




 


miR-19a
UGUGCAAAUCUAUGCAA
330
miR-19a; miR-19a-13



AACUGA




 


miR-19b
UGUGCAAAUCCAUGCAA
331
miR-19b-1; miR-19b-2



AACUGA




 


miR-20
UAAAGUGCUUAUAGUGC
332
miR-20 (miR-20a)



AGGUA




 


miR-21
UAGCUUAUCAGACUGAU
333
miR-21; miR-21-17



GUUGA




 


miR-22
AAGCUGCCAGUUGAAGA
334
miR-22



ACUGU




 


miR-23a
AUCACAUUGCCAGGGAU
335
miR-23a



UUCC




 


miR-23b
AUCACAUUGCCAGGGAU
336
miR-23b



UACCAC




 


miR-24
UGGCUCAGUUCAGCAGG
337
miR-24-1; miR-24-2;



AACAG

miR-24-19; miR-24-9


 


miR-25
CAUUGCACUUGUCUCGG
338
miR-25



UCUGA




 


miR-26a
UUCAAGUAAUCCAGGAU
339
miR-26a; miR-26a-1;



AGGCU

miR-26a-2


 


miR-26b
UUCAAGUAAUUCAGGAU
340
miR-26b



AGGU




 


miR-27a
UUCACAGUGGCUAAGUU
341
miR-27a



CCGCC




 


miR-27b
UUCACAGUGGCUAAGUU
342
miR-27b-1; miR-27b-2



CUG




 


miR-28
AAGGAGCUCACAGUCUA
343
miR-28



UUGAG




 


miR-29a
CUAGCACCAUCUGAAAU
344
miR-29a-2; miR-29a



CGGUU




 


miR-29b
UAGCACCAUUUGAAAUC
345
miR-29b-1; miR-29b-2



AGU




 


miR-29c
UAGCACCAUUUGAAAUC
346
miR-29c



GGUUA




 


miR-30a-5p
UGUAAACAUCCUCGACU
347
miR-30a



GGAAGC




 


miR-30a-3p
CUUUCAGUCGGAUGUUU
348
miR-30a



GCAGC




 


miR-30b
UGUAAACAUCCUACACU
349
miR-30b-1; miR-30b-2



CAGC




 


miR-30c
UGUAAACAUCCUACACU
350
miR-30c



CUCAGC




 


miR-30d
UGUAAACAUCCCCGACU
351
miR-30d



GGAAG




 


miR-30e
UGUAAACAUCCUUGACU
352
miR-30e



GGA




 


miR-31
GGCAAGAUGCUGGCAUA
353
miR-31



GCUG




 


miR-32
UAUUGCACAUUACUAAG
354
miR-32



UUGC




 


miR-33
GUGCAUUGUAGUUGCAU
355
miR-33; miR-33b



UG




 


miR-34a
UGGCAGUGUCUUAGCUG
356
miR-34a



GUUGU




 


miR-34b
AGGCAGUGUCAUUAGCU
357
miR-34b



GAUUG




 


miR-34c
AGGCAGUGUAGUUAGCU
358
miR-34c



GAUUG




 


miR-92
UAUUGCACUUGUCCCGG
359
miR-92-2; miR-92-1



CCUGU




 


miR-93
AAAGUGCUGUUCGUGCA
360
miR-93-1; miR-93-2



GGUAG




 


miR-95
UUCAACGGGUAUUUAUU
361
miR-95



GAGCA




 


miR-96
UUUGGCACUAGCACAUU
362
miR-96



UUUGC




 


miR-98
UGAGGUAGUAAGUUGUA
363
miR-98



UUGUU




 


miR-99a
AACCCGUAGAUCCGAUC
364
miR-99a



UUGUG




 


miR-99b
CACCCGUAGAACCGACC
365
miR-99b



UUGCG




 


miR-100
UACAGUACUGUGAUAAC
366
miR-100



UGAAG




 


miR-101
UACAGUACUGUGAUAAC
367
miR-101-1; miR-101-2



UGAAG




 


miR-103
AGCAGCAUUGUACAGGG
368
miR-103-1



CUAUGA




 


miR-105
UCAAAUGCUCAGACUCC
369
miR-105



UGU




 


miR-106-a
AAAAGUGCUUACAGUGC
370
miR-106-a



AGGUAGC




 


miR-106-b
UAAAGUGCUGACAGUGC
371
miR-106-b



AGAU




 


miR-107
AGCAGCAUUGUACAGGG
372
miR-107



CUAUCA




 


miR-122a
UGGAGUGUGACAAUGGU
373
miR-122a-1; miR-122a-2



GUUUGU




 


miR-124a
UUAAGGCACGCGGUGAA
374
miR-124a-1; miR-124a-2; miR-



UGCCA

124a-3


 


miR-125a
UCCCUGAGACCCUUUAA
375
miR-125a-1; miR-125a-2



CCUGUG




 


miR-125b
UCCCUGAGACCCUAACU
376
miR-125b-1; miR-125b-2



UGUGA




 


miR-126*
CAUUAUUACUUUUGGUA
377
miR-126-1; miR-126-2



CGCG




 


miR-126
UCGUACCGUGAGUAAUA
378
miR-126-1; miR-126-2



AUGC




 


miR-127
UCGGAUCCGUCUGAGCU
379
miR-127-1; miR-127-2



UGGCU




 


miR-128a
UCACAGUGAACCGGUCU
380
miR-128; miR-128a



CUUUU




 


miR-128b
UCACAGUGAACCGGUCU
381
miR-128b



CUUUC




 


miR-129
CUUUUUGCGGUCUGGGC
382
miR-129-1; miR-129-2



UUGC




 


miR-130a
CAGUGCAAUGUUAAAAG
383
miR-130a



GGC




 


miR-130b
CAGUGCAAUGAUGAAAG
384
miR-130b



GGCAU




 


miR-132
UAACAGUCUACAGCCAU
385
miR-132-1



GGUCG




 


miR-133a
UUGGUCCCCUUCAACCA
386
miR-133a-1; miR-133a-2



GCUGU




 


miR-133b
UUGGUCCCCUUCAACCA
387
miR-133b



GCUA




 


miR-134
UGUGACUGGUUGACCAG
388
miR-134-1; miR-134-2



AGGG




 


miR-135a
UAUGGCUUUUUAUUCCU
389
miR-135a; miR-135a-2 (miR-



AUGUGA

135-2)


 


miR-135b
UAUGGCUUUUCAUUCCU
390
miR-135b



AUGUG




 


miR-136
ACUCCAUUUGUUUUGAU
391
miR-136-1; miR-136-2



GAUGGA




 


miR-137
UAUUGCUUAAGAAUACG
392
miR-137



CGUAG




 


miR-138
AGCUGGUGUUGUGAAUC
393
miR-138-1; miR-138-2


 


miR-139
UCUACAGUGCACGUGUC
394
miR-139



U




 


miR-140
AGUGGUUUUACCCUAUG
395
miR-140; miR-140as;



GUAG

miR-140s


 


miR-141
AACACUGUCUGGUAAAG
396
miR-141-1; miR-141-2



AUGG




 


miR-142-3p
UGUAGUGUUUCCUACUU
397
miR-142



UAUGGA




 


miR-142-5p
CAUAAAGUAGAAAGCAC
398
miR-142



UAC




 


miR-143
UGAGAUGAAGCACUGUA
399
miR-143-1



GCUCA




 


miR-144
UACAGUAUAGAUGAUGU
400
miR-144-1; miR-144-2



ACUAG




 


miR-145
GUCCAGUUUUCCCAGGA
401
miR-145-1; miR-145-2



AUCCCUU




 


miR-146
UGAGAACUGAAUUCCAU
402
miR-146-1; miR-146-2



GGGUU




 


miR-147
GUGUGUGGAAAUGCUUC
403
miR-147



UGC




 


miR-148a
UCAGUGCACUACAGAAC
404
miR-148a (miR-148)



UUUGU




 


miR-148b
UCAGUGCAUCACAGAAC
405
miR-148b



UUUGU




 


miR-149
UCUGGCUCCGUGUCUUC
406
miR-149



ACUCC




 


miR-150
UCUCCCAACCCUUGUACC
407
miR-150-1; miR-150-2



AGUG




 


miR-151
ACUAGACUGAAGCUCCU
408
miR-151



UGAGG




 


miR-152
UCAGUGCAUGACAGAAC
409
miR-152-1; miR-152-2



UUGG




 


miR-153
UUGCAUAGUCACAAAAG
410
miR-153-1-1; miR-153-1-2; miR-



UGA

153-2-1; miR-153-2-2


 


miR-154
UAGGUUAUCCGUGUUGC
411
miR-154-1; miR-154-2



CUUCG




 


miR-154*
AAUCAUACACGGUUGAC
412
miR-154-1; miR-154-2



CUAUU




 


miR-155
UUAAUGCUAAUCGUGAU
413
miR-155



AGGGG




 


miR-181a
AACAUUCAACGCUGUCG
414
miR-181a



GUGAGU




 


miR-181b
AACAUUCAUUGCUGUCG
415
miR-181b-1; miR-181b-2



GUGGGUU




 


miR-181c
AACAUUCAACCUGUCGG
416
miR-181c



UGAGU




 


miR-182
UUUGGCAAUGGUAGAAC
417
miR-182; miR-182as



UCACA




 


miR-182*
UGGUUCUAGACUUGCCA
418
miR-182; miR-182as



ACUA




 


miR-183
UAUGGCACUGGUAGAAU
419
miR-183



UCACUG




 


miR-184
UGGACGGAGAACUGAUA
420
miR-184-1; miR-184-2



AGGGU




 


miR-185
UGGAGAGAAAGGCAGUU
421
miR-185-1; miR-185-2



C




 


miR-186
CAAAGAAUUCUCCUUUU
422
miR-186-1; miR-186-2



GGGCUU




 


miR-187
UCGUGUCUUGUGUUGCA
423
miR-187



GCCG




 


miR-188
CAUCCCUUGCAUGGUGG
424
miR-188



AGGGU




 


miR-189
GUGCCUACUGAGCUGAU
425
miR-189-1; miR-189-2



AUCAGU




 


miR-190
UGAUAUGUUUGAUAUAU
426
miR-190-1; miR-190-2



UAGGU




 


miR-191
CAACGGAAUCCCAAAAG
427
miR-191-1; miR-191-2



CAGCU




 


miR-192
CUGACCUAUGAAUUGAC
428
miR-192



AGCC




 


miR-193
AACUGGCCUACAAAGUC
429
miR-193-1; miR-193-2



CCAG




 


miR-194
UGUAACAGCAACUCCAU
430
miR-194-1; miR-194-2



GUGGA




 


miR-195
UAGCAGCACAGAAAUAU
431
miR-195-1; miR-195-2



UGGC




 


miR-196a
UAGGUAGUUUCAUGUUG
432
miR-196a; miR-196a-2 



UUGG

(miR196-2)


 


miR-196b
UAGGUAGUUUCCUGUUG
433
miR-196b



UUGG




 


miR-197
UUCACCACCUUCUCCACC
434
miR-197



CAGC




 


miR-198
GGUCCAGAGGGGAGAUA
435
miR-198



GG




 


miR-199a
CCCAGUGUUCAGACUAC
436
miR-199a-1; miR-199a-2



CUGUUC




 


miR-199a*
UACAGUAGUCUGCACAU
437
miR-199a-1; miR-199a-2; miR-



UGGUU

199s; miR-199b


 


miR-199b
CCCAGUGUUUAGACUAU
438
miR-199b



CUGUUC




 


miR-200a
UAACACUGUCUGGUAAC
439
miR-200a



GAUGU




 


miR-200b
CUCUAAUACUGCCUGGU
440
miR-200b



AAUGAUG




 


miR-200c
AAUACUGCCGGGUAAUG
441
miR-200c



AUGGA




 


miR-202
AGAGGUAUAGGGCAUGG
442
miR-202



GAAGA




 


miR-203
GUGAAAUGUUUAGGACC
443
miR-203



ACUAG




 


miR-204
UUCCCUUUGUCAUCCUA
444
miR-204



UGCCU




 


miR-205
UCCUUCAUUCCACCGGA
445
miR-205



GUCUG




 


miR-206
UGGAAUGUAAGGAAGUG
446
miR-206-1; miR-206-2



UGUGG




 


miR-208
AUAAGACGAGCAAAAAG
447
miR-208



CUUGU




 


miR-210
CUGUGCGUGUGACAGCG
448
miR-210



GCUG




 


miR-211
UUCCCUUUGUCAUCCUU
449
miR-211



CGCCU




 


miR-212
UAACAGUCUCCAGUCAC
450
miR-212



GGCC




 


miR-213
ACCAUCGACCGUUGAUU
451
miR-213



GUACC




 


miR-214
ACAGCAGGCACAGACAG
452
miR-214



GCAG




 


miR-215
AUGACCUAUGAAUUGAC
453
miR-215



AGAC




 


miR-216
UAAUCUCAGCUGGCAAC
454
miR-216



UGUG




 


miR-217
UACUGCAUCAGGAACUG
455
miR-217



AUUGGAU




 


miR-218
UUGUGCUUGAUCUAACC
456
miR-218-1; miR-218-2



AUGU




 


miR-219
UGAUUGUCCAAACGCAA
457
miR-219; miR-219-1;



UUCU

miR-219-2


 


miR-220
CCACACCGUAUCUGACA
458
miR-220



CUUU




 


miR-221
AGCUACAUUGUCUGCUG
459
miR-221



GGUUUC




 


miR-222
AGCUACAUCUGGCUACU
460
miR-222



GGGUCUC




 


miR-223
UGUCAGUUUGUCAAAUA
461
miR-223



CCCC




 


miR-224
CAAGUCACUAGUGGUUC
462
miR-224



CGUUUA




 


miR-296
AGGGCCCCCCCUCAAUCC
463
miR-296



UGU




 


miR-299
UGGUUUACCGUCCCACA
464
miR-299



UACAU




 


miR-301
CAGUGCAAUAGUAUUGU
465
miR-301



CAAAGC




 


miR-302a
UAAGUGCUUCCAUGUUU
466
miR-302a



UGGUGA




 


miR-302b*
ACUUUAACAUGGAAGUG
467
miR-302b



CUUUCU




 


miR-302b
UAAGUGCUUCCAUGUUU
468
miR-302b



UAGUAG




 


miR-302c*
UUUAACAUGGGGGUACC
469
miR-302c



UGCUG




 


miR-302c
UAAGUGCUUCCAUGUUU
470
miR-302c



CAGUGG




 


miR-302d
UAAGUGCUUCCAUGUUU
471
miR-302d



GAGUGU




 


miR-320
AAAAGCUGGGUUGAGAG
472
miR-320



GGCGAA




 


miR-321
UAAGCCAGGGAUUGUGG
473
miR-321



GUUC




 


miR-323
GCACAUUACACGGUCGA
474
miR-323



CCUCU




 


miR-324-5p
CGCAUCCCCUAGGGCAU
475
miR-324



UGGUGU




 


miR-324-3p
CCACUGCCCCAGGUGCU
476
miR-324



GCUGG




 


miR-325
CCUAGUAGGUGUCCAGU
477
miR-325



AAGU




 


miR-326
CCUCUGGGCCCUUCCUCC
478
miR-326



AG




 


miR-328
CUGGCCCUCUCUGCCCUU
479
miR-328



CCGU




 


miR-330
GCAAAGCACACGGCCUG
480
miR-330



CAGAGA




 


miR-331
GCCCCUGGGCCUAUCCU
481
miR-331



AGAA




 


miR-335
UCAAGAGCAAUAACGAA
482
miR-335



AAAUGU




 


miR-337
UCCAGCUCCUAUAUGAU
483
miR-337



GCCUUU




 


miR-338
UCCAGCAUCAGUGAUUU
484
miR-338



UGUUGA




 


miR-339
UCCCUGUCCUCCAGGAG
485
miR-339



CUCA




 


miR-340
UCCGUCUCAGUUACUUU
486
miR-340



AUAGCC




 


miR-342
UCUCACACAGAAAUCGC
487
miR-342



ACCCGUC




 


miR-345
UGCUGACUCCUAGUCCA
488
miR-345



GGGC




 


miR-346
UGUCUGCCCGCAUGCCU
489
miR-346



GCCUCU




 


miR-367
AAUUGCACUUUAGCAAU
490
miR-367



GGUGA




 


miR-368
ACAUAGAGGAAAUUCCA
491
miR-368



CGUUU




 


miR-369
AAUAAUACAUGGUUGAU
492
miR-369



CUUU




 


miR-370
GCCUGCUGGGGUGGAAC
493
miR-370



CUGG




 


miR-371
GUGCCGCCAUCUUUUGA
494
miR-371



GUGU




 


miR-372
AAAGUGCUGCGACAUUU
495
miR-372



GAGCGU




 


miR-373*
ACUCAAAAUGGGGGCGC
496
miR-373



UUUCC




 


miR-373
GAAGUGCUUCGAUUUUG
497
miR-373



GGGUGU




 


miR-374
UUAUAAUACAACCUGAU
498
miR-374



AAGUG









The present invention encompasses methods of diagnosing or prognosticating whether a subject has, or is at risk for developing, a cancer and/or myeloproliferative disorder. The methods comprise determining the level of at least one miR gene product in a sample from the subject and comparing the level of the miR gene product in the sample to a control. As used herein, a “subject” can be any mammal that has, or is suspected of having, a cancer and/or myeloproliferative disorder. In a preferred embodiment, the subject is a human who has, or is suspected of having, a cancer, myeloproliferative disorder and/or a platelet disorder.
The level of at least one miR gene product can be measured in cells of a biological sample obtained from the subject. For example, a tissue sample can be removed from a subject suspected of having cancer and/or a myeloproliferative disorder by conventional biopsy techniques. In another embodiment, a blood sample can be removed from the subject, and white blood cells can be isolated for DNA extraction by standard techniques. In one embodiment, the blood or tissue sample is obtained from the subject prior to initiation of radiotherapy, chemotherapy or other therapeutic treatment. A corresponding control tissue or blood sample, or a control reference sample (e.g., obtained from a population of control samples), can be obtained from unaffected tissues of the subject, from a normal human individual or population of normal individuals, or from cultured cells corresponding to the majority of cells in the subject's sample. The control tissue or blood sample can then processed along with the sample from the subject, so that the levels of miR gene product produced from a given miR gene in cells from the subject's sample can be compared to the corresponding miR gene product levels from cells of the control sample. Alternatively, a reference sample can be obtained and processed separately (e.g., at a different time) from the test sample and the level of a miR gene product produced from a given miR gene in cells from the test sample can be compared to the corresponding miR gene product level from the reference sample.
In one embodiment, the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is “upregulated”). As used herein, expression of a miR gene product is “upregulated” when the amount of miR gene product in a cell or tissue sample from a subject is greater than the amount of the same gene product in a control (e.g., a reference standard, a control cell sample, a control tissue sample). In another embodiment, the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is “downregulated”). As used herein, expression of a miR gene is “downregulated” when the amount of miR gene product produced from that gene in a cell or tissue sample from a subject is less than the amount produced from the same gene in a control cell or tissue sample. The relative miR gene expression in the control and normal samples can be determined with respect to one or more RNA expression standards. The standards can comprise, for example, a zero miR gene expression level, the miR gene expression level in a standard cell line, the miR gene expression level in unaffected tissues of the subject, or the average level of miR gene expression previously obtained for a population of normal human controls (e.g., a control reference standard).
An alteration (i.e., an increase or decrease) in the level of a miR gene product in the sample obtained from the subject, relative to the level of a corresponding miR gene product in a control sample, is indicative of the presence of cancer and/or a myeloproliferative disorder in the subject. In one embodiment, the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample. miR gene products having higher expression levels in cancer cell lines (e.g., AMKL cell lines) than control cells (e.g., in vitro CD34+-differentiated megakaryocytes) are described and exemplified herein (see, e.g., Example 5). In one embodiment, the at least one miR gene product is selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135, miR-20 and combinations thereof. In another embodiment, the at least one miR gene product is selected from the group consisting of miR-101, miR-126, miR-106, miR-20 and miR-135 and combinations thereof. In yet another embodiment, the at least one miR gene product is selected from the group consisting of miR-106, miR-20 and miR-135 and combinations thereof. As described and exemplified herein, the increased expression of such miR gene products discriminates cancerous cells from corresponding non-cancerous cells.
As described herein, the diagnostic and prognostic methods of the invention can be used to diagnose or prognosticate cancers and/or myeloproliferative disorders. In particular embodiments, the diagnostic and prognostic methods are used to diagnose or prognosticate a cancer in a subject, tissue sample, cell sample or fluid sample. The diagnostic and prognostic methods can be used to diagnose or prognosticate any type of cancer. In particular embodiments, the diagnostic and prognostic methods can be used to diagnose or prognosticate a leukemia. In one embodiment, the leukemia that is diagnosed or prognosticated is acute myeloid leukemia (e.g., acute megakaryoblastic leukemia). In other embodiments, the diagnostic and prognostic methods can be used to diagnose or prognosticate multiple myeloma.
The diagnostic and prognostic methods of the invention can also be used to diagnose or prognosticate hematologic malignancies (e.g., myeloproliferative disorders). In one embodiment, the myeloproliferative disorder that is diagnosed or prognosticated is selected from the group consisting of essential thrombocytemia (ET), polycythemia vera (PV), myelodisplasia, myelofibrosis (e.g., agnogenic myeloid metaplasia (AMM) (also referred to as idiopathic myelofibrosis)) and chronic myelogenous leukemia (CML).
In particular embodiments, the diagnostic, prognostic and therapeutic methods of the invention can also be used to diagnose, prognosticate and/or treat platelet disorders (e.g., inherited platelet disorders). For example, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat defects in platelet-vessel wall interactions (i.e., disorders of adhesion). Such adhesion disorders include, e.g., von Willebrand disease (deficiency or defect in plasma vWF) and Bernard-Soulier syndrome (deficiency or defect in GPIb). In other embodiments, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat defects in platelet-platelet interaction (i.e., disorders of aggregation). Such aggregation disorders include, e.g., congenital afibrinogenemia (deficiency of plasma fibrinogen) and glanzmann thrombasthenia (deficiency or defect in GPIIb-IIIa). In other embodiments, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat disorders of platelet secretion and abnormalities of granules. Such disorders of platelet secretion and abnormalities of granules include, e.g., storage pool deficiency and Quebec platelet disorder. In yet other embodiments, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat disorders of platelet secretion and signal transduction (primary secretion defects). Such primary secretion defects include, e.g., defects in platelet-agonist interaction (receptor defects) (e.g., thromboxane A2, collagen, ADP, epinephrine), defects in G-protein activation (e.g., Gαq deficiency, Gas abnormalities, Gαi deficiency), defects in phosphatidylinositol metabolism (e.g., phospholipase C-2 deficiency), defects in calcium mobilization, defects in protein phosphorylation (pleckstrin) PKC-y deficiency, and abnormalities in arachidonic acid pathways and thromboxane synthesis (e.g., cyclooxygenase deficiency, thromboxane synthase deficiency). In other embodiments, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat defects in cytoskeletal regulation (e.g., Wiskott-Aldrich syndrome). In still other embodiments, the diagnostic, prognostic and therapeutic methods can be used to diagnose, prognosticate and/or treat disorders of platelet coagulant-protein interaction (membrane phospholipid defects) (e.g., Scott syndrome). Other platelet disorders (e.g., inherited platelet disorders) can also be diagnosed, prognosticated and/or treated using the methods of the invention.
The invention also provides methods of determining the prognosis of a subject with cancer and/or a myeloproliferative disorder. In this method, the level of at least one miR gene product, which is associated with a particular prognosis in cancer and/or a myeloproliferative disorder (e.g., a good or positive prognosis, a poor or adverse prognosis), is measured in a test sample from the subject. An alteration (e.g., an increase, a decrease) in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject having a cancer and/or myeloproliferative disorder with a particular prognosis. In one embodiment, the miR gene product is associated with an adverse (i.e., poor) prognosis. Examples of an adverse prognosis include, but are not limited to, low survival rate and rapid disease progression. In one embodiment, the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in a control sample (i.e., it is upregulated). In a particular embodiment, the at least one miR gene product that is upregulated is selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135, miR-20 and combinations thereof. In another embodiment, the at least one miR gene product that is upregulated is selected from the group consisting of miR-101, miR-126, miR-106, miR-20 and miR-135 and combinations thereof. In yet another embodiment, the at least one miR gene product that is upregulated is selected from the group consisting of miR-106, miR-20 and miR-135 and combinations thereof. The increased expression of such miR gene products can correlate with an adverse prognosis and the severity of a subject's cancer and/or myeloproliferative disorder.
In certain embodiments of the diagnostic and prognostic methods described herein, the level of the at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to a microarray that comprises miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample.
Identification of targets of particular miR gene products (e.g., those miR gene products exhibiting upregulated or downregulated expression relative to a control sample) can aid in elucidating mechanisms of action of microRNAs. As described and exemplified herein, particular targets and putative targets of select microRNAs were identified (see, e.g., Tables 2, 3 and 5 and Exemplification). For example, the transcription factor MAFB was identified as a target of mi-130a (Example 2). Similarly, HOXA1 was identified as a target of miR-10a (Example 5). For both miRs, direct interaction of the miR with the 3′ UTR of its respective target was demonstrated (Examples 2 and 5). Moreover, an inverse relation in the expression of the miR and its respective target were demonstrated. Thus, expression of pre-miR-130a resulted in decreased expression of MAFB (see, e.g., FIG. 2C) while expression of pre-miR-10a resulted in decreased expression of HOXA1 (see, e.g., FIGS. 3C, 3F and 3G). Thus, in one embodiment, expression of target genes of particular microRNAs (e.g., those listed in Tables 2, 3 and 5) can be used to diagnose cancer and/or a myeloproliferative disorder. Such target genes display inverse expression to the respective miR that targets it. One of skill in the art can measure the expression levels of any of these target genes using known methods and/or methods described herein for measuring the expression levels of microRNAs (e.g., quantitative or semi-quantitative RT-PCR, Northern blot analysis, solution hybridization detection, microarray analysis), without undue experimentation. In particular embodiments, the target gene that is measured is MAFB or HOXA1.
The level of the at least one miR gene product can be measured using a variety of techniques that are well known to those of skill in the art (e.g., quantitative or semi-quantitative RT-PCR, Northern blot analysis, solution hybridization detection). In a particular embodiment, the level of at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to one or more miRNA-specific probe oligonucleotides (e.g., a microarray that comprises miRNA-specific probe oligonucleotides) to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample. An alteration in the signal of at least one miRNA in the test sample relative to the control sample is indicative of the subject either having, or being at risk for developing cancer and/or a myeloproliferative disorder. In one embodiment, the signal of at least one miRNA is upregulated, relative to the signal generated from the control sample. In another embodiment, the signal of at least one miRNA is downregulated, relative to the signal generated from the control sample. In a particular embodiment, the microarray comprises miRNA-specific probe oligonucleotides for a substantial portion of all known human miRNAs (e.g., the miRNAs listed in Tables 1a and 1b plus other known or discovered miRNAs). In a further embodiment, the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135, miR-20 and a combination thereof. In one embodiment, the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-101, miR-126, miR-106, miR-20, miR-135 and a combination thereof.
The microarray can be prepared from gene-specific oligonucleotide probes generated from known miRNA sequences. The array may contain two different oligonucleotide probes for each miRNA, one containing the active, mature sequence and the other being specific for the precursor of the miRNA. The array may also contain controls, such as one or more mouse sequences differing from human orthologs by only a few bases, which can serve as controls for hybridization stringency conditions. tRNAs and other RNAs (e.g., rRNAs, mRNAs) from both species may also be printed on the microchip, providing an internal, relatively stable, positive control for specific hybridization. One or more appropriate controls for non-specific hybridization may also be included on the microchip. For this purpose, sequences are selected based upon the absence of any homology with any known miRNAs.
The microarray may be fabricated using techniques known in the art. For example, probe oligonucleotides of an appropriate length, e.g., 40 nucleotides, are 5′-amine modified at position C6 and printed using commercially available microarray systems, e.g., the GeneMachine OmniGridTM 100 Microarrayer and Amersham CodeLinkTM activated slides. Labeled cDNA oligomer corresponding to the target RNAs is prepared by reverse transcribing the target RNA with labeled primer. Following first strand synthesis, the RNA/DNA hybrids are denatured to degrade the RNA templates. The labeled target cDNAs thus prepared are then hybridized to the microarray chip under hybridizing conditions, e.g., 6×SSPE/30% formamide at 25° C. for 18 hours, followed by washing in 0.75×TNT at 37° C. for 40 minutes. At positions on the array where the immobilized probe DNA recognizes a complementary target cDNA in the sample, hybridization occurs. The labeled target cDNA marks the exact position on the array where binding occurs, allowing automatic detection and quantification. The output consists of a list of hybridization events, indicating the relative abundance of specific cDNA sequences, and therefore the relative abundance of the corresponding complementary miRs, in the patient sample. According to one embodiment, the labeled cDNA oligomer is a biotin-labeled cDNA, prepared from a biotin-labeled primer. The microarray is then processed by direct detection of the biotin-containing transcripts using, e.g., Streptavidin-Alexa647 conjugate, and scanned utilizing conventional scanning methods. Image intensities of each spot on the array are proportional to the abundance of the corresponding miR in the patient sample.
The use of the array has several advantages for miRNA expression detection. First, the global expression of several hundred genes can be identified in the same sample at one time point. Second, through careful design of the oligonucleotide probes, expression of both mature and precursor molecules can be identified. Third, in comparison with Northern blot analysis, the chip requires a small amount of RNA, and provides reproducible results using 2.5 μg of total RNA. The relatively limited number of miRNAs (a few hundred per species) allows the construction of a common microarray for several species, with distinct oligonucleotide probes for each. Such a tool would allow for analysis of trans-species expression for each known miR under various conditions.
In addition to use for quantitative expression level assays of specific miRs, a microchip containing miRNA-specific probe oligonucleotides corresponding to a substantial portion of the miRNome, preferably the entire miRNome, may be employed to carry out miR gene expression profiling, for analysis of miR expression patterns. Distinct miR signatures can be associated with established disease markers, or directly with a disease state.
According to the expression profiling methods described herein, total RNA from a sample from a subject suspected of having a cancer and/or a myeloproliferative disorder is quantitatively reverse transcribed to provide a set of labeled target oligodeoxynucleotides complementary to the RNA in the sample. The target oligodeoxynucleotides are then hybridized to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the sample. The result is a hybridization profile for the sample representing the expression pattern of miRNA in the sample. The hybridization profile comprises the signal from the binding of the target oligodeoxynucleotides from the sample to the miRNA-specific probe oligonucleotides in the microarray. The profile may be recorded as the presence or absence of binding (signal vs. zero signal). More preferably, the profile recorded includes the intensity of the signal from each hybridization. The profile is compared to the hybridization profile generated from a normal (e.g., noncancerous, non-myeloproliferative disorder) control sample or reference sample. An alteration in the signal is indicative of the presence of, or propensity to develop, cancer in the subject.
Other techniques for measuring miR gene expression are also within the skill in the art, and include various techniques for measuring rates of RNA transcription and degradation.
The invention also provides methods of diagnosing whether a subject has, or is at risk for developing, a cancer and/or myeloproliferative disorder with an adverse prognosis. In this method, the level of at least one miR gene product, which is associated with an adverse prognosis in a cancer and/or myeloproliferative disorder, is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides. The target oligodeoxynucleotides are then hybridized to one or more miRNA-specific probe oligonucleotides (e.g., a microarray that comprises miRNA-specific probe oligonucleotides) to provide a hybridization profile for the test sample, and the test sample hybridization profile is compared to a hybridization profile generated from a control sample. An alteration in the signal of at least one miRNA in the test sample relative to the control sample is indicative of the subject either having, or being at risk for developing, a cancer and/or myeloproliferative disorder with an adverse prognosis. miRs suitable for use in this method include, e.g., those that are upregulated in cancerous cells (e.g., AMKL cells).
In particular embodiments of the diagnostic, prognostic and therapeutic methods of the invention, as well as the pharmaceutical compositions of the invention, the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-71, miR-7-2, miR-7-3, miR-9, miR-9-1, miR-10a, miR-15a, miR-15b, miR-16-1, miR-16-2, miR-17-5p, miR-20a, miR-21, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30, miR-30a-5p, miR-30c, miR-30d, miR-31, miR-32, miR-34, miR-34a, miR-34a prec, miR-34a-1, miR-34a-2, miR-92-2, miR-96, miR-99a, miR-99b prec, miR-100, miR-103, miR-106a, miR-107, miR-123, miR-124a-1, miR-125b-1, miR-125b-2, miR-126*, miR-127, miR-128b, miR-129, miR-129-1/2 prec, miR-132, miR-135-1, miR-136, miR-137, miR-141, miR-142-as, miR-143, miR-146, miR-148, miR-149, miR-153, miR-155, miR 159-1, miR-181, miR-181b-1, miR-182, miR-186, miR-191, miR-192, miR-195, miR-196-1, miR-196-1 prec, miR-196-2, miR-199a-1, miR-199a-2, miR-199b, miR-200b, miR-202, miR-203, miR-204, miR-205, miR-210, miR-211, miR-212, miR-214, miR-215, miR-217, miR-221 and/or miR-223.
As described herein, the level of a miR gene product in a sample can be measured using any technique that is suitable for detecting RNA expression levels in a biological sample. Suitable techniques (e.g., Northern blot analysis, RT-PCR, in situ hybridization) for determining RNA expression levels in a biological sample (e.g., cells, tissues) are well known to those of skill in the art. In a particular embodiment, the level of at least one miR gene product is detected using Northern blot analysis. For example, total cellular RNA can be purified from cells by homogenization in the presence of nucleic acid extraction buffer, followed by centrifugation. Nucleic acids are precipitated, and DNA is removed by treatment with DNase and precipitation. The RNA molecules are then separated by gel electrophoresis on agarose gels according to standard techniques, and transferred to nitrocellulose filters. The RNA is then immobilized on the filters by heating. Detection and quantification of specific RNA is accomplished using appropriately labeled DNA or RNA probes complementary to the RNA in question. See, for example, Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold Spring Harbor Laboratory Press, 1989, Chapter 7, the entire disclosure of which is incorporated by reference.
Suitable probes (e.g., DNA probes, RNA probes) for Northern blot hybridization of a given miR gene product can be produced from the nucleic acid sequences provided in Table 1a and Table 1b and include, but are not limited to, probes having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% complementarity to a miR gene product of interest, as well as probes that have complete complementarity to a miR gene product of interest. Methods for preparation of labeled DNA and RNA probes, and the conditions for hybridization thereof to target nucleotide sequences, are described in Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold Spring Harbor Laboratory Press, 1989, Chapters 10 and 11, the disclosures of which are incorporated herein by reference.
For example, the nucleic acid probe can be labeled with, e.g., a radionuclide, such as 3H, 32P, 33P, 14C or 35S; a heavy metal; a ligand capable of functioning as a specific binding pair member for a labeled ligand (e.g., biotin, avidin or an antibody); a fluorescent molecule; a chemiluminescent molecule; an enzyme or the like.
Probes can be labeled to high specific activity by either the nick translation method of Rigby et al. (1977), J. Mol. Biol. 113:237-251 or by the random priming method of Fienberg et al. (1983), Anal. Biochem. 132:6-13, the entire disclosures of which are incorporated herein by reference. The latter is the method of choice for synthesizing 32P-labeled probes of high specific activity from single-stranded DNA or from RNA templates. For example, by replacing preexisting nucleotides with highly radioactive nucleotides according to the nick translation method, it is possible to prepare 32P-labeled nucleic acid probes with a specific activity well in excess of 108 cpm/microgram. Autoradiographic detection of hybridization can then be performed by exposing hybridized filters to photographic film. Densitometric scanning of the photographic films exposed by the hybridized filters provides an accurate measurement of miR gene transcript levels. Using another approach, miR gene transcript levels can be quantified by computerized imaging systems, such as the Molecular Dynamics 400-B 2D Phosphorimager available from Amersham Biosciences, Piscataway, N.J.
Where radionuclide labeling of DNA or RNA probes is not practical, the random-primer method can be used to incorporate an analogue, for example, the dTTP analogue 5-(N—(N-biotinyl-epsilon-aminocaproyl)-3-aminoallyl)deoxyuridine triphosphate, into the probe molecule. The biotinylated probe oligonucleotide can be detected by reaction with biotin-binding proteins, such as avidin, streptavidin and antibodies (e.g., anti-biotin antibodies) coupled to fluorescent dyes or enzymes that produce color reactions.
In addition to Northern and other RNA hybridization techniques, determining the levels of RNA transcripts can be accomplished using the technique of in situ hybridization. This technique requires fewer cells than the Northern blotting technique and involves depositing whole cells onto a microscope cover slip and probing the nucleic acid content of the cell with a solution containing radioactive or otherwise labeled nucleic acid (e.g., cDNA or RNA) probes. This technique is particularly well-suited for analyzing tissue biopsy samples from subjects. The practice of the in situ hybridization technique is described in more detail in U.S. Pat. No. 5,427,916, the entire disclosure of which is incorporated herein by reference. Suitable probes for in situ hybridization of a given miR gene product can be produced from the nucleic acid sequences provided in Table 1a and Table 1b, and include, but are not limited to, probes having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% complementarity to a miR gene product of interest, as well as probes that have complete complementarity to a miR gene product of interest, as described above.
The relative number of miR gene transcripts in cells can also be determined by reverse transcription of miR gene transcripts, followed by amplification of the reverse-transcribed transcripts by polymerase chain reaction (RT-PCR), for example, as exemplified herein. The levels of miR gene transcripts can be quantified in comparison with an internal standard, for example, the level of mRNA from a “housekeeping” gene present in the same sample. A suitable “housekeeping” gene for use as an internal standard includes, e.g., U6 small nuclear RNA, myosin or glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Methods for performing quantitative and semi-quantitative RT-PCR, and variations thereof, are well known to those of skill in the art.
In some instances, it may be desirable to simultaneously determine the expression level of a plurality of different miR gene products in a sample. In other instances, it may be desirable to determine the expression level of the transcripts of all known miR genes correlated with a cancer and/or myeloproliferative disorder. Assessing cancer-specific expression levels for hundreds of miR genes or gene products is time consuming and requires a large amount of total RNA (e.g., at least 20 μg for each Northern blot) and autoradiographic techniques that require radioactive isotopes.
To overcome these limitations, an oligolibrary, in microchip format (i.e., a microarray), may be constructed containing a set of oligonucleotide (e.g., oligodeoxynucleotide) probes that are specific for a set of miR genes. Using such a microarray, the expression level of multiple microRNAs in a biological sample can be determined by reverse transcribing the RNAs to generate a set of target oligodeoxynucleotides, and hybridizing them to probe the oligonucleotides on the microarray to generate a hybridization, or expression, profile. The hybridization profile of the test sample can then be compared to that of a control sample to determine which microRNAs have an altered expression level in cancer cells and/or cells exhibiting a myeloproliferative disorder. As used herein, “probe oligonucleotide” or “probe oligodeoxynucleotide” refers to an oligonucleotide that is capable of hybridizing to a target oligonucleotide. “Target oligonucleotide” or “target oligodeoxynucleotide” refers to a molecule to be detected (e.g., via hybridization). By “miR-specific probe oligonucleotide” or “probe oligonucleotide specific for a miR” is meant a probe oligonucleotide that has a sequence selected to hybridize to a specific miR gene product, or to a reverse transcript of the specific miR gene product.
An “expression profile” or “hybridization profile” of a particular sample is essentially a fingerprint of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. That is, normal tissue, cell or fluid samples may be distinguished from corresponding cancerous and/or myeloproliferative disorder-exhibiting tissue, cell or fluid samples. Within cancerous and/or myeloproliferative disorder-exhibiting tissue, cell or fluid samples, different prognosis states (for example, good or poor long term survival prospects) may be determined. By comparing expression profiles of cancerous and/or myeloproliferative disorder-exhibiting tissue, cell or fluid samples in different states, information regarding which genes are important (including both upregulation and downregulation of genes) in each of these states is obtained. The identification of sequences that are differentially expressed in cancerous and/or myeloproliferative disorder-exhibiting tissue, cell or fluid samples, as well as differential expression resulting in different prognostic outcomes, allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated (e.g., to determine whether a chemotherapeutic drug acts to improve the long-term prognosis in a particular subject). Similarly, diagnosis may be done or confirmed by comparing samples from a subject with known expression profiles. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates that suppress the cancer and/or myeloproliferative disorder expression profile or convert a poor prognosis profile to a better prognosis profile.
Without wishing to be bound by any one theory, it is believed that alterations in the level of one or more miR gene products in cells can result in the deregulation of one or more intended targets for these miRs, which can lead to aberrant megakaryocytic differentiation and/or the formation of cancer, a myeloproliferative disorder and/or a platelet disorder. Therefore, altering the level of the miR gene product (e.g., by decreasing the level of a miR that is upregulated in cancerous and/or myeloproliferative disorder-exhibiting cells, by increasing the level of a miR that is downregulated in cancerous and/or myeloproliferative disorder-exhibiting cells) may successfully treat the cancer, myeloproliferative disorder and/or platelet disorder.
Accordingly, the present invention encompasses methods of treating a cancer and/or myeloproliferative disorder in a subject, wherein at least one miR gene product is deregulated (e.g., downregulated, upregulated) in the cells (e.g., cancerous cells and/or myeloproliferative disorder-exhibiting cells) of the subject. In one embodiment, the level of at least one miR gene product in a test sample (e.g., a sample comprising cancerous and/or myeloproliferative disorder-exhibiting tissues, cells or fluid) is greater than the level of the corresponding miR gene product in a control or reference sample. In another embodiment, the level of at least one miR gene product in a test sample (e.g., a sample comprising cancerous and/or myeloproliferative disorder-exhibiting tissues, cells or fluid) is less than the level of the corresponding miR gene product in a control sample. When the at least one isolated miR gene product is downregulated in the test sample (e.g., a sample comprising cancerous and/or myeloproliferative disorder-exhibiting tissues, cells or fluid), the method comprises administering an effective amount of the at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, such that proliferation of the cancerous and/or myeloproliferative disorder-exhibiting cells in the subject is inhibited. For example, when a miR gene product is downregulated in a cancer cell in a subject, administering an effective amount of an isolated miR gene product to the subject can inhibit proliferation of the cancer cell. The isolated miR gene product that is administered to the subject can be identical to an endogenous wild-type miR gene product (e.g., a miR gene product shown in Table 1a or Table 1b) that is downregulated in the cancer cell or it can be a variant or biologically-active fragment thereof. As defined herein, a “variant” of a miR gene product refers to a miRNA that has less than 100% identity to a corresponding wild-type miR gene product and possesses one or more biological activities of the corresponding wild-type miR gene product. Examples of such biological activities include, but are not limited to, inhibition of expression of a target RNA molecule (e.g., inhibiting translation of a target RNA molecule, modulating the stability of a target RNA molecule, inhibiting processing of a target RNA molecule) and inhibition of a cellular process associated with cancer and/or a myeloproliferative disorder (e.g., cell differentiation, cell growth, cell death). These variants include species variants and variants that are the consequence of one or more mutations (e.g., a substitution, a deletion, an insertion) in a miR gene. In certain embodiments, the variant is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a corresponding wild-type miR gene product.
As defined herein, a “biologically-active fragment” of a miR gene product refers to an RNA fragment of a miR gene product that possesses one or more biological activities of a corresponding wild-type miR gene product. As described above, examples of such biological activities include, but are not limited to, inhibition of expression of a target RNA molecule and inhibition of a cellular process associated with cancer and/or a myeloproliferative disorder. In certain embodiments, the biologically-active fragment is at least about 5, 7, 10, 12, 15, or 17 nucleotides in length. In a particular embodiment, an isolated miR gene product can be administered to a subject in combination with one or more additional anti-cancer treatments. Suitable anti-cancer treatments include, but are not limited to, chemotherapy, radiation therapy and combinations thereof (e.g., chemoradiation).
When the at least one isolated miR gene product is upregulated in the cancer cells, the method comprises administering to the subject an effective amount of a compound that inhibits expression of the at least one miR gene product, such that proliferation of the cancer and/or myeloproliferative disorder-exhibiting cells is inhibited. Such compounds are referred to herein as miR gene expression-inhibition compounds. Examples of suitable miR gene expression-inhibition compounds include, but are not limited to, those described herein (e.g., double-stranded RNA, antisense nucleic acids and enzymatic RNA molecules). In a particular embodiment, a miR gene expression-inhibiting compound can be administered to a subject in combination with one or more additional anti-cancer treatments. Suitable anti-cancer treatments include, but are not limited to, chemotherapy, radiation therapy and combinations thereof (e.g., chemoradiation).
As described, when the at least one isolated miR gene product is upregulated in cancer cells (e.g., AMKL cells), the method comprises administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of cancer cells is inhibited. In one embodiment, the compound for inhibiting expression of the at least one miR gene product inhibits a miR gene product selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135, miR-20 and a combination thereof. In another embodiment, the compound for inhibiting expression of the at least one miR gene product inhibits a miR gene product selected from the group consisting of miR-101, miR-126, miR-106, miR-20, miR-135 and a combination thereof. In yet another embodiment, the compound for inhibiting expression of the at least one miR gene product inhibits a miR gene product selected from the group consisting of miR-106, miR-20, miR-135 and a combination thereof.
As described and exemplified herein, the transcription factor MAFB, which is upregulated in megakaryocytic differentiation, is a target of miR-130a. Moreover, an inverse relation in the expression of miR-130a and its respective target were demonstrated. Thus, expression of pre-miR-130a resulted in decreased expression of MAFB (see, e.g., FIG. 2C). MAFB is known to be deregulated in cancer (e.g., multiple myeloma and acute myeloid leukemia). For example, ectopic expression of MAFB has been observed in human myeloma cells carrying (14; 20)(q32; q11) chromosomal translocations (Hanamura, I., et al. (2001) Jpn. J. Cancer Res. 92(6):638-644 (2001)). Accordingly, in one embodiment, the invention is a method of treating a cancer and/or myeloproliferative disorder in a subject comprising administering an effective amount of at least one miR gene product or an isolated variant or biologically-active fragment thereof to the subject, wherein:
the cancer and/or myeloproliferative disorder is associated with overexpression of a MAFB gene product; and
the at least one miR gene product binds to, and decreases expression of, the MAFB gene product.
In one embodiment, the at least one miR gene product or isolated variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product (e.g., complementary to the 3′ UTR of MAFB). In a particular embodiment, the at least one miR gene product is miR-130a or an isolated variant or biologically-active fragment thereof.
Also as described and exemplified herein, mRNA of HOXA1, one of the members of the HOX family of proteins, is upregulated 7-fold in megakaryocytic differentiation (see, e.g., Example 4). Moreover, HOXA1 is a target of miR-10a and its expression is inversely related to the expression of miR-10a. Thus, expression of pre-miR-10a resulted in decreased expression of HOXA1 (see, e.g., FIGS. 3C, 3F and 3G). HOXA1. Expression of HOXA1 has been demonstrated to be sufficient to result in the oncogenic transformation of immortalized human mammary epithelial cells with aggressive in vivo tumor formation (Zhang, X., et al., (2002) J. Biol. Chem. 278(9):7580-7590). Further, forced expression of HOXA1 in mammary carcinoma cells, in a Bcl-2-dependent manner, resulted in a dramatic enhancement of anchorage-independent proliferation and colony formation in soft agar. Id. Accordingly, in one embodiment, the invention is a method of treating a cancer and/or myeloproliferative disorder in a subject comprising administering an effective amount of at least one miR gene product or an isolated variant or biologically-active fragment thereof to the subject, wherein:
the cancer and/or myeloproliferative disorder is associated with overexpression of a HOXA1 gene product; and
the at least one miR gene product binds to, and decreases expression of, the HOXA1 gene product.
In one embodiment, the at least one miR gene product or isolated variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product (e.g., complementary to the 3′ UTR of HOXA1). In a particular embodiment, the at least one miR gene product is miR-10a or an isolated variant or biologically-active fragment thereof.
In a related embodiment, the methods of treating cancer and/or a myeloproliferative disorder in a subject additionally comprise the step of first determining the amount of at least one miR gene product in a sample from the subject, and comparing that level of the miR gene product to the level of a corresponding miR gene product in a control. If expression of the miR gene product is deregulated (e.g., downregulated, upregulated) in the sample from the subject, the methods further comprise altering the amount of the at least one miR gene product expressed in the sample from the subject. In one embodiment, the amount of the miR gene product expressed in the sample from the subject is less than the amount of the miR gene product expressed in the control, and an effective amount of the miR gene product, or an isolated variant or biologically-active fragment thereof, is administered to the subject. In another embodiment, the amount of the miR gene product expressed in the sample from the subject is greater than the amount of the miR gene product expressed in the control, and an effective amount of at least one compound for inhibiting expression of the at least one miR gene is administered to the subject. Suitable miRs and compounds that inhibit expression of miR genes include, for example, those described herein.
The terms “treat”, “treating” and “treatment”, as used herein, refer to ameliorating symptoms associated with a disease or condition, for example, cancer and/or a myeloproliferative disorder, including preventing or delaying the onset of the disease symptoms, and/or lessening the severity or frequency of symptoms of the disease or condition. The terms “subject”, “patient” and “individual” are defined herein to include animals, such as mammals, including, but not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent, or murine species. In a preferred embodiment, the animal is a human.
As used herein, an “effective amount” of an isolated miR gene product is an amount sufficient to inhibit proliferation of cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder) in a subject suffering from cancer and/or a myeloproliferative disorder. One skilled in the art can readily determine an effective amount of a miR gene product to be administered to a given subject, by taking into account factors, such as the size and weight of the subject; the extent of disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.
For example, an effective amount of an isolated miR gene product can be based on the approximate weight of a tumor mass to be treated. The approximate weight of a tumor mass can be determined by calculating the approximate volume of the mass, wherein one cubic centimeter of volume is roughly equivalent to one gram. An effective amount of the isolated miR gene product based on the weight of a tumor mass can be in the range of about 10-500 micrograms/gram of tumor mass. In certain embodiments, the tumor mass can be at least about 10 micrograms/gram of tumor mass, at least about 60 micrograms/gram of tumor mass or at least about 100 micrograms/gram of tumor mass.
An effective amount of an isolated miR gene product can also be based on the approximate or estimated body weight of a subject to be treated. Preferably, such effective amounts are administered parenterally or enterally, as described herein. For example, an effective amount of the isolated miR gene product that is administered to a subject can range from about 5-3000 micrograms/kg of body weight, from about 700-1000 micrograms/kg of body weight, or greater than about 1000 micrograms/kg of body weight.
One skilled in the art can also readily determine an appropriate dosage regimen for the administration of an isolated miR gene product to a given subject. For example, a miR gene product can be administered to the subject once (e.g., as a single injection or deposition). Alternatively, a miR gene product can be administered once or twice daily to a subject for a period of from about three to about twenty-eight days, more particularly from about seven to about ten days. In a particular dosage regimen, a miR gene product is administered once a day for seven days. Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of the miR gene product administered to the subject can comprise the total amount of gene product administered over the entire dosage regimen.
As used herein, an “isolated” miR gene product is one that is synthesized, or altered or removed from the natural state through human intervention. For example, a synthetic miR gene product, or a miR gene product partially or completely separated from the coexisting materials of its natural state, is considered to be “isolated.” An isolated miR gene product can exist in a substantially-purified form, or can exist in a cell into which the miR gene product has been delivered. Thus, a miR gene product that is deliberately delivered to, or expressed in, a cell is considered an “isolated” miR gene product. A miR gene product produced inside a cell from a miR precursor molecule is also considered to be an “isolated” molecule. According to the invention, the isolated miR gene products described herein can be used for the manufacture of a medicament for treating cancer and/or a myeloproliferative disorder in a subject (e.g., a human).
Isolated miR gene products can be obtained using a number of standard techniques. For example, the miR gene products can be chemically synthesized or recombinantly produced using methods known in the art. In one embodiment, miR gene products are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. Commercial suppliers of synthetic RNA molecules or synthesis reagents include, e.g., Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, Colo., U.S.A.), Pierce Chemical (part of Perbio Science, Rockford, Ill., U.S.A.), Glen Research (Sterling, Va., U.S.A.), ChemGenes (Ashland, Mass., U.S.A.) and Cruachem (Glasgow, UK).
Alternatively, the miR gene products can be expressed from recombinant circular or linear DNA plasmids using any suitable promoter. Suitable promoters for expressing RNA from a plasmid include, e.g., the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art. The recombinant plasmids of the invention can also comprise inducible or regulatable promoters for expression of the miR gene products in cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder).
The miR gene products that are expressed from recombinant plasmids can be isolated from cultured cell expression systems by standard techniques. The miR gene products that are expressed from recombinant plasmids can also be delivered to, and expressed directly in, cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder). The use of recombinant plasmids to deliver the miR gene products to cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder) is discussed in more detail below.
The miR gene products can be expressed from a separate recombinant plasmid, or they can be expressed from the same recombinant plasmid. In one embodiment, the miR gene products are expressed as RNA precursor molecules from a single plasmid, and the precursor molecules are processed into the functional miR gene product by a suitable processing system, including, but not limited to, processing systems extant within a cancer cell. Other suitable processing systems include, e.g., the in vitro Drosophila cell lysate system (e.g., as described in U.S. Published Patent Application No. 2002/0086356 to Tuschl et al., the entire disclosure of which is incorporated herein by reference) and the E. coli RNAse III system (e.g., as described in U.S. Published Patent Application No. 2004/0014113 to Yang et al., the entire disclosure of which is incorporated herein by reference).
Selection of plasmids suitable for expressing the miR gene products, methods for inserting nucleic acid sequences into the plasmid to express the gene products, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art. See, for example, Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat. Biotechnol, 20:446-448; Brummelkamp et al. (2002), Science 296:550-553; Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al. (2002), Genes Dev. 16:948-958; Lee et al. (2002), Nat. Biotechnol. 20:500-505; and Paul et al. (2002), Nat. Biotechnol. 20:505-508, the entire disclosures of which are incorporated herein by reference.
In one embodiment, a plasmid expressing the miR gene products comprises a sequence encoding a miR precursor RNA under the control of the CMV intermediate-early promoter. As used herein, “under the control” of a promoter means that the nucleic acid sequences encoding the miR gene product are located 3′ of the promoter, so that the promoter can initiate transcription of the miR gene product coding sequences.
The miR gene products can also be expressed from recombinant viral vectors. It is contemplated that the miR gene products can be expressed from two separate recombinant viral vectors, or from the same viral vector. The RNA expressed from the recombinant viral vectors can either be isolated from cultured cell expression systems by standard techniques, or can be expressed directly in cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder). The use of recombinant viral vectors to deliver the miR gene products to cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder) is discussed in more detail below.
The recombinant viral vectors of the invention comprise sequences encoding the miR gene products and any suitable promoter for expressing the RNA sequences. Suitable promoters include, but are not limited to, the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the miR gene products in a cancer cell.
Any viral vector capable of accepting the coding sequences for the miR gene products can be used; for example, vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g., lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of the viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.
For example, lentiviral vectors of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors of the invention can be made to target different cells by engineering the vectors to express different capsid protein serotypes. For example, an AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector. Techniques for constructing AAV vectors that express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz, J. E., et al. (2002), J. Virol. 76:791-801, the entire disclosure of which is incorporated herein by reference.
Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing RNA into the vector, methods of delivering the viral vector to the cells of interest, and recovery of the expressed RNA products are within the skill in the art. See, for example, Dornburg (1995), Gene Therapy 2:301-310; Eglitis (1988), Biotechniques 6:608-614; Miller (1990), Hum. Gene Therapy 1:5-14; and Anderson (1998), Nature 392:25-30, the entire disclosures of which are incorporated herein by reference.
Particularly suitable viral vectors are those derived from AV and AAV. A suitable AV vector for expressing the miR gene products, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia et al. (2002), Nat. Biotech. 20:1006-1010, the entire disclosure of which is incorporated herein by reference. Suitable AAV vectors for expressing the miR gene products, methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski et al. (1987), J. Virol. 61:3096-3101; Fisher et al. (1996), J. Virol., 70:520-532; Samulski et al. (1989), J. Virol. 63:3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are incorporated herein by reference. In one embodiment, the miR gene products are expressed from a single recombinant AAV vector comprising the CMV intermediate early promoter.
In a certain embodiment, a recombinant AAV viral vector of the invention comprises a nucleic acid sequence encoding a miR precursor RNA in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter. As used herein, “in operable connection with a polyT termination sequence” means that the nucleic acid sequences encoding the sense or antisense strands are immediately adjacent to the polyT termination signal in the 5′ direction. During transcription of the miR sequences from the vector, the polyT termination signals act to terminate transcription.
In other embodiments of the treatment methods of the invention, an effective amount of at least one compound that inhibits miR expression can be administered to the subject. As used herein, “inhibiting miR expression” means that the production of the precursor and/or active, mature form of miR gene product after treatment is less than the amount produced prior to treatment. One skilled in the art can readily determine whether miR expression has been inhibited in cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder), using, for example, the techniques for determining miR transcript level discussed herein. Inhibition can occur at the level of gene expression (i.e., by inhibiting transcription of a miR gene encoding the miR gene product) or at the level of processing (e.g., by inhibiting processing of a miR precursor into a mature, active miR).
As used herein, an “effective amount” of a compound that inhibits miR expression is an amount sufficient to inhibit proliferation of cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder) in a subject suffering from cancer and/or a myeloproliferative disorder. One skilled in the art can readily determine an effective amount of a miR expression-inhibiting compound to be administered to a given subject, by taking into account factors, such as the size and weight of the subject; the extent of disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.
For example, an effective amount of the expression-inhibiting compound can be based on the approximate weight of a tumor mass to be treated, as described herein. An effective amount of a compound that inhibits miR expression can also be based on the approximate or estimated body weight of a subject to be treated, as described herein.
One skilled in the art can also readily determine an appropriate dosage regimen for administering a compound that inhibits miR expression to a given subject, as described herein. Suitable compounds for inhibiting miR gene expression include double-stranded RNA (such as short- or small-interfering RNA or “siRNA”), antisense nucleic acids, and enzymatic RNA molecules, such as ribozymes. Each of these compounds can be targeted to a given miR gene product and interfere with the expression (e.g., by inhibiting translation, by inducing cleavage and/or degradation) of the target miR gene product.
For example, expression of a given miR gene can be inhibited by inducing RNA interference of the miR gene with an isolated double-stranded RNA (“dsRNA”) molecule which has at least 90%, for example, at least 95%, at least 98%, at least 99%, or 100%, sequence homology with at least a portion of the miR gene product. In a particular embodiment, the dsRNA molecule is a “short or small interfering RNA” or “siRNA.”
siRNA useful in the present methods comprise short double-stranded RNA from about 17 nucleotides to about 29 nucleotides in length, preferably from about 19 to about 25 nucleotides in length. The siRNA comprise a sense RNA strand and a complementary antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter “base-paired”). The sense strand comprises a nucleic acid sequence that is substantially identical to a nucleic acid sequence contained within the target miR gene product.
As used herein, a nucleic acid sequence in an siRNA that is “substantially identical” to a target sequence contained within the target mRNA is a nucleic acid sequence that is identical to the target sequence, or that differs from the target sequence by one or two nucleotides. The sense and antisense strands of the siRNA can comprise two complementary, single-stranded RNA molecules, or can comprise a single molecule in which two complementary portions are base-paired and are covalently linked by a single-stranded “hairpin” area.
The siRNA can also be altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or to one or more internal nucleotides of the siRNA, or modifications that make the siRNA resistant to nuclease digestion, or the substitution of one or more nucleotides in the siRNA with deoxyribonucleotides.
One or both strands of the siRNA can also comprise a 3′ overhang. As used herein, a “3′ overhang” refers to at least one unpaired nucleotide extending from the 3′-end of a duplexed RNA strand. Thus, in certain embodiments, the siRNA comprises at least one 3′ overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxyribonucleotides) in length, from 1 to about 5 nucleotides in length, from 1 to about 4 nucleotides in length, or from about 2 to about 4 nucleotides in length. In a particular embodiment, the 3′ overhang is present on both strands of the siRNA, and is 2 nucleotides in length. For example, each strand of the siRNA can comprise 3′ overhangs of dithymidylic acid (“TT”) or diuridylic acid (“uu”).
The siRNA can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing dsRNA or siRNA molecules are described in U.S. Published Patent Application No. 2002/0173478 to Gewirtz and in U.S. Published Patent Application No. 2004/0018176 to Reich et al., the entire disclosures of both of which are incorporated herein by reference.
Expression of a given miR gene can also be inhibited by an antisense nucleic acid. As used herein, an “antisense nucleic acid” refers to a nucleic acid molecule that binds to target RNA by means of RNA-RNA, RNA-DNA or RNA-peptide nucleic acid interactions, which alters the activity of the target RNA. Antisense nucleic acids suitable for use in the present methods are single-stranded nucleic acids (e.g., RNA, DNA, RNA-DNA chimeras, peptide nucleic acids (PNA)) that generally comprise a nucleic acid sequence complementary to a contiguous nucleic acid sequence in a miR gene product. The antisense nucleic acid can comprise a nucleic acid sequence that is 50-100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in a miR gene product. Nucleic acid sequences of particular human miR gene products are provided in Table 1a and Table 1b. Without wishing to be bound by any theory, it is believed that the antisense nucleic acids activate RNase H or another cellular nuclease that digests the miR gene product/antisense nucleic acid duplex.
Antisense nucleic acids can also contain modifications to the nucleic acid backbone or to the sugar and base moieties (or their equivalent) to enhance target specificity, nuclease resistance, delivery or other properties related to efficacy of the molecule. Such modifications include cholesterol moieties, duplex intercalators, such as acridine, or one or more nuclease-resistant groups.
Antisense nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing are within the skill in the art; see, e.g., Stein and Cheng (1993), Science 261:1004 and U.S. Pat. No. 5,849,902 to Woolf et al., the entire disclosures of which are incorporated herein by reference.
Expression of a given miR gene can also be inhibited by an enzymatic nucleic acid. As used herein, an “enzymatic nucleic acid” refers to a nucleic acid comprising a substrate binding region that has complementarity to a contiguous nucleic acid sequence of a miR gene product, and which is able to specifically cleave the miR gene product. The enzymatic nucleic acid substrate binding region can be, for example, 50-100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in a miR gene product. The enzymatic nucleic acids can also comprise modifications at the base, sugar, and/or phosphate groups. An exemplary enzymatic nucleic acid for use in the present methods is a ribozyme.
The enzymatic nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing dsRNA or siRNA molecules are described in Werner and Uhlenbeck (1995), Nucleic Acids Res. 23:2092-96; Hammann et al. (1999), Antisense and Nucleic Acid Drug Dev. 9:25-31; and U.S. Pat. No. 4,987,071 to Cech et al, the entire disclosures of which are incorporated herein by reference.
Administration of at least one miR gene product, or at least one compound for inhibiting miR expression, will inhibit the proliferation of cells (e.g., cancerous cells, cells exhibiting a myeloproliferative disorder) in a subject who has a cancer and/or a myeloproliferative disorder. As used herein, to “inhibit the proliferation of cancerous cells or cells exhibiting a myeloproliferative disorder” means to kill the cells, or permanently or temporarily arrest or slow the growth of the cells. Inhibition of cell proliferation can be inferred if the number of such cells in the subject remains constant or decreases after administration of the miR gene products or miR gene expression-inhibiting compounds. An inhibition of proliferation of cancerous cells or cells exhibiting a myeloproliferative disorder can also be inferred if the absolute number of such cells increases, but the rate of tumor growth decreases.
The number of cancer cells in the body of a subject can be determined by direct measurement, or by estimation from the size of primary or metastatic tumor masses. For example, the number of cancer cells in a subject can be measured by immunohistological methods, flow cytometry, or other techniques designed to detect characteristic surface markers of cancer cells.
The size of a tumor mass can be ascertained by direct visual observation, or by diagnostic imaging methods, such as X-ray, magnetic resonance imaging, ultrasound, and scintigraphy. Diagnostic imaging methods used to ascertain size of the tumor mass can be employed with or without contrast agents, as is known in the art. The size of a tumor mass can also be ascertained by physical means, such as palpation of the tissue mass or measurement of the tissue mass with a measuring instrument, such as a caliper.
The miR gene products or miR gene expression-inhibiting compounds can be administered to a subject by any means suitable for delivering these compounds to cells (e.g., cancer cells, cells exhibiting a myeloproliferative disorder) of the subject. For example, the miR gene products or miR expression-inhibiting compounds can be administered by methods suitable to transfect cells of the subject with these compounds, or with nucleic acids comprising sequences encoding these compounds. In one embodiment, the cells are transfected with a plasmid or viral vector comprising sequences encoding at least one miR gene product or miR gene expression-inhibiting compound.
Transfection methods for eukaryotic cells are well known in the art, and include, e.g., direct injection of the nucleic acid into the nucleus or pronucleus of a cell; electroporation; liposome transfer or transfer mediated by lipophilic materials; receptor-mediated nucleic acid delivery, bioballistic or particle acceleration; calcium phosphate precipitation, and transfection mediated by viral vectors.
For example, cells can be transfected with a liposomal transfer compound, e.g., DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methylsulfate, Boehringer-Mannheim) or an equivalent, such as LIPOFECTIN. The amount of nucleic acid used is not critical to the practice of the invention; acceptable results may be achieved with 0.1-100 micrograms of nucleic acid/105 cells. For example, a ratio of about 0.5 micrograms of plasmid vector in 3 micrograms of DOTAP per 105 cells can be used.
A miR gene product or miR gene expression-inhibiting compound can also be administered to a subject by any suitable enteral or parenteral administration route. Suitable enteral administration routes for the present methods include, e.g., oral, rectal, or intranasal delivery. Suitable parenteral administration routes include, e.g., intravascular administration (e.g., intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue injection (e.g., peri-tumoral and intra-tumoral injection, intra-retinal injection, or subretinal injection); subcutaneous injection or deposition, including subcutaneous infusion (such as by osmotic pumps); direct application to the tissue of interest, for example by a catheter or other placement device (e.g., a retinal pellet or a suppository or an implant comprising a porous, non-porous, or gelatinous material); and inhalation. Particularly suitable administration routes are injection, infusion and direct injection into the tumor.
In the present methods, a miR gene product or miR gene product expression-inhibiting compound can be administered to the subject either as naked RNA, in combination with a delivery reagent, or as a nucleic acid (e.g., a recombinant plasmid or viral vector) comprising sequences that express the miR gene product or miR gene expression-inhibiting compound. Suitable delivery reagents include, e.g., the Mirus Transit TKO lipophilic reagent; LIPOFECTIN; lipofectamine; cellfectin; polycations (e.g., polylysine) and liposomes.
Recombinant plasmids and viral vectors comprising sequences that express the miR gene products or miR gene expression-inhibiting compounds, and techniques for delivering such plasmids and vectors to cancer cells, are discussed herein and/or are well known in the art.
In a particular embodiment, liposomes are used to deliver a miR gene product or miR gene expression-inhibiting compound (or nucleic acids comprising sequences encoding them) to a subject. Liposomes can also increase the blood half-life of the gene products or nucleic acids. Suitable liposomes for use in the invention can be formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of factors, such as the desired liposome size and half-life of the liposomes in the blood stream. A variety of methods are known for preparing liposomes, for example, as described in Szoka et al. (1980), Ann. Rev. Biophys. Bioeng. 9:467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are incorporated herein by reference.
The liposomes for use in the present methods can comprise a ligand molecule that targets the liposome to cancer cells. Ligands that bind to receptors prevalent in cancer cells, such as monoclonal antibodies that bind to tumor cell antigens, are preferred.
The liposomes for use in the present methods can also be modified so as to avoid clearance by the mononuclear macrophage system (“MMS”) and reticuloendothelial system (“RES”). Such modified liposomes have opsonization-inhibition moieties on the surface or incorporated into the liposome structure. In a particularly preferred embodiment, a liposome of the invention can comprise both an opsonization-inhibition moiety and a ligand.
Opsonization-inhibiting moieties for use in preparing the liposomes of the invention are typically large hydrophilic polymers that are bound to the liposome membrane. As used herein, an opsonization-inhibiting moiety is “bound” to a liposome membrane when it is chemically or physically attached to the membrane, e.g., by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of membrane lipids. These opsonization-inhibiting hydrophilic polymers form a protective surface layer that significantly decreases the uptake of the liposomes by the MMS and RES; e.g., as described in U.S. Pat. No. 4,920,016, the entire disclosure of which is incorporated herein by reference.
Opsonization-inhibiting moieties suitable for modifying liposomes are preferably water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, and more preferably from about 2,000 to about 20,000 daltons. Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) or derivatives thereof; e.g., methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers, such as polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, e.g., polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GM1. Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable. In addition, the opsonization-inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyleneamine, or polynucleotide. The opsonization-inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, e.g., galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; aminated polysaccharides or oligosaccharides (linear or branched); or carboxylated polysaccharides or oligosaccharides, e.g., reacted with derivatives of carbonic acids with resultant linking of carboxylic groups. Preferably, the opsonization-inhibiting moiety is a PEG, PPG, or a derivative thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called “PEGylated liposomes.”
The opsonization-inhibiting moiety can be bound to the liposome membrane by any one of numerous well-known techniques. For example, an N-hydroxysuccinimide ester of PEG can be bound to a phosphatidyl-ethanolamine lipid-soluble anchor, and then bound to a membrane. Similarly, a dextran polymer can be derivatized with a stearylamine lipid-soluble anchor via reductive amination using Na(CN)BH3 and a solvent mixture, such as tetrahydrofuran and water in a 30:12 ratio at 60° C.
Liposomes modified with opsonization-inhibition moieties remain in the circulation much longer than unmodified liposomes. For this reason, such liposomes are sometimes called “stealth” liposomes. Stealth liposomes are known to accumulate in tissues fed by porous or “leaky” microvasculature. Thus, tissue characterized by such microvasculature defects, for example, solid tumors, will efficiently accumulate these liposomes; see Gabizon, et al. (1988), Proc. Natl. Acad. Sci., U.S.A., 18:6949-53. In addition, the reduced uptake by the RES lowers the toxicity of stealth liposomes by preventing significant accumulation of the liposomes in the liver and spleen. Thus, liposomes that are modified with opsonization-inhibition moieties are particularly suited to deliver the miR gene products or miR gene expression-inhibition compounds (or nucleic acids comprising sequences encoding them) to tumor cells.
The miR gene products or miR gene expression-inhibition compounds can be formulated as pharmaceutical compositions, sometimes called “medicaments,” prior to administering them to a subject, according to techniques known in the art. Accordingly, the invention encompasses pharmaceutical compositions for treating cancer and/or a myeloproliferative disorder.
In one embodiment, the pharmaceutical composition of the invention comprises at least one miR expression-inhibition compound and a pharmaceutically-acceptable carrier. In a particular embodiment, the at least one miR expression-inhibition compound is specific for a miR gene product whose expression is greater in cancer cells than control cells (i.e., it is upregulated). In another embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135 and miR-20. In another embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-101, miR-126, miR-106, miR-20, and miR-135. In yet another embodiment, the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-106, miR-20 and miR-135.
In other embodiments, the pharmaceutical compositions comprise an effective amount of at least one miR gene product, or an isolated variant or biologically-active fragment thereof, and a pharmaceutically-acceptable carrier. In one embodiment, the invention is a pharmaceutical composition for treating a cancer and/or a myeloproliferative disorder, wherein the cancer and/or myeloproliferative disorder is associated with overexpression of a MAFB gene product. In this embodiment, the pharmaceutical composition comprises at least one miR gene product that binds to, and decreases expression of, the MAFB gene product. In a particular embodiment, the at least one miR gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product. In another embodiment, the at least one miR gene product is miR-130a or an isolated variant or biologically-active fragment thereof.
In one embodiment, the invention is a pharmaceutical composition for treating a cancer and/or a myeloproliferative disorder, wherein the cancer and/or myeloproliferative disorder is associated with overexpression of a HOXA1 gene product. In this embodiment, the pharmaceutical composition comprises at least one miR gene product that binds to, and decreases expression of, the HOXA1 gene product. In a particular embodiment, the at least one miR gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product. In another embodiment, the at least one miR gene product is miR-10a or an isolated variant or biologically-active fragment thereof.
Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. As used herein, “pharmaceutical compositions” include formulations for human and veterinary use. Methods for preparing pharmaceutical compositions of the invention are within the skill in the art, for example, as described in Remington's Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, Pa. (1985), the entire disclosure of which is incorporated herein by reference.
The present pharmaceutical compositions comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) (e.g., 0.1 to 90% by weight), or a physiologically-acceptable salt thereof, mixed with a pharmaceutically-acceptable carrier. In certain embodiments, the pharmaceutical composition of the invention additionally comprises one or more anti-cancer agents (e.g., chemotherapeutic agents). The pharmaceutical formulations of the invention can also comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound), which are encapsulated by liposomes and a pharmaceutically-acceptable carrier. In one embodiment, the pharmaceutical composition comprises a miR gene or gene product that is not miR-15, miR-16, miR-143 and/or miR-145.
Especially suitable pharmaceutically-acceptable carriers are water, buffered water, normal saline, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.
In a particular embodiment, the pharmaceutical compositions of the invention comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) that is resistant to degradation by nucleases. One skilled in the art can readily synthesize nucleic acids that are nuclease resistant, for example by incorporating one or more ribonucleotides that is modified at the 2′-position into the miR gene product. Suitable 2′-modified ribonucleotides include those modified at the 2′-position with fluoro, amino, alkyl, alkoxy and O-allyl.
Pharmaceutical compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives. Suitable pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH adjusting agents. Suitable additives include, e.g., physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA or DTPA-bisamide) or calcium chelate complexes (such as, for example, calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate). Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.
For solid pharmaceutical compositions of the invention, conventional nontoxic solid pharmaceutically-acceptable carriers can be used; for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
For example, a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%, preferably 25%-75%, of the at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising sequences encoding them). A pharmaceutical composition for aerosol (inhalational) administration can comprise 0.01-20% by weight, preferably 1%-10% by weight, of the at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) encapsulated in a liposome as described above, and a propellant. A carrier can also be included as desired; e.g., lecithin for intranasal delivery.
The pharmaceutical compositions of the invention can further comprise one or more anti-cancer agents. In a particular embodiment, the compositions comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) and at least one chemotherapeutic agent. Chemotherapeutic agents that are suitable for the methods of the invention include, but are not limited to, DNA-alkylating agents, anti-tumor antibiotic agents, anti-metabolic agents, tubulin stabilizing agents, tubulin destabilizing agents, hormone antagonist agents, topoisomerase inhibitors, protein kinase inhibitors, HMG-CoA inhibitors, CDK inhibitors, cyclin inhibitors, caspase inhibitors, metalloproteinase inhibitors, antisense nucleic acids, triple-helix DNAs, nucleic acids aptamers, and molecularly-modified viral, bacterial and exotoxic agents. Examples of suitable agents for the compositions of the present invention include, but are not limited to, cytidine arabinoside, methotrexate, vincristine, etoposide (VP-16), doxorubicin (adriamycin), cisplatin (CDDP), dexamethasone, arglabin, cyclophosphamide, sarcolysin, methylnitrosourea, fluorouracil, 5-fluorouracil (5FU), vinblastine, camptothecin, actinomycin-D, mitomycin C, hydrogen peroxide, oxaliplatin, irinotecan, topotecan, leucovorin, carmustine, streptozocin, CPT-11, taxol, tamoxifen, dacarbazine, rituximab, daunorubicin, 1-β-D-arabinofuranosylcytosine, imatinib, fludarabine, docetaxel and FOLFOX4.
The invention also encompasses methods of identifying an anti-cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product in the cell. In one embodiment, the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in cancer cells (e.g., in AMKL cells). A decrease in the level of the miR gene product that is associated with increased expression levels in cancer, relative to a suitable control (e.g., the level of the miR gene product in control cells), is indicative of the test agent being an anti-cancer agent. In a particular embodiment, the at least one miR gene product associated with increased expression levels in cancer cells is selected from the group consisting of miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33, miR-135 and miR-20. In another embodiment, the at least one miR gene product associated with increased expression levels in cancer cells is selected from the group consisting of miR-101, miR-126, miR-106, miR-20 and miR-135. In yet another embodiment, the at least one miR gene product associated with increased expression levels in cancer cells is selected from the group consisting of miR-106, miR-20 and miR-135. In one embodiment, the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-71, miR-7-2, miR-7-3, miR-9, miR-9-1, miR-10a, miR-15a, miR-15b, miR-16-1, miR-16-2, miR-17-5p, miR-20a, miR-21, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30, miR-30a-5p, miR-30c, miR-30d, miR-31, miR-32, miR-34, miR-34a, miR-34a prec, miR-34a-1, miR-34a-2, miR-92-2, miR-96, miR-99a, miR-99b prec, miR-100, miR-103, miR-106a, miR-107, miR-123, miR-124a-1, miR-125b-1, miR-125b-2, miR-126*, miR-127, miR-128b, miR-129, miR-129-1/2 prec, miR-132, miR-135-1, miR-136, miR-137, miR-141, miR-142-as, miR-143, miR-146, miR-148, miR-149, miR-153, miR-155, miR 159-1, miR-181, miR-181b-1, miR-182, miR-186, miR-191, miR-192, miR-195, miR-196-1, miR-196-1 prec, miR-196-2, miR-199a-1, miR-199a-2, miR-199b, miR-200b, miR-202, miR-203, miR-204, miR-205, miR-210, miR-211, miR-212, miR-214, miR-215, miR-217, miR-221 and/or miR-223.
In one embodiment, the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in cancerous cells. An increase in the level of the miR gene product in the cell, relative to a suitable control (e.g., the level of the miR gene product in a control cell), is indicative of the test agent being an anti-cancer agent.
Suitable agents include, but are not limited to drugs (e.g., small molecules, peptides), and biological macromolecules (e.g., proteins, nucleic acids). The agent can be produced recombinantly, synthetically, or it may be isolated (i.e., purified) from a natural source. Various methods for providing such agents to a cell (e.g., transfection) are well known in the art, and several of such methods are described hereinabove. Methods for detecting the expression of at least one miR gene product (e.g., Northern blotting, in situ hybridization, RT-PCR, expression profiling) are also well known in the art. Several of these methods are also described herein.
The invention will now be illustrated by the following non-limiting examples.
EXEMPLIFICATION
Unless otherwise noted, the following materials and methods were used in the Examples.
Material and Methods
Cell Lines and Human CD34+ Cells.
The human chronic myeloid leukemia (CML) blast crisis cell lines K-562 and MEG-01 were obtained from American Type Tissue Culture (ATCC, Manassas, Va.) and maintained in RPMI 1640 (GIBCO, Carlsbad, Calif.) containing 10% FBS with penicillin-gentamycin at 37° C. with 5% CO2. The human megakaryoblastic leukemia cells UT-7, and CMK, and the chronic myeloid leukemia (CML) in blast crisis LAMA were obtained from DSMZ (Braunsweig, Germany). All cells were maintained in RPMI medium 1640 with 20% FBS and antibiotics, except UT-7 which is factor-dependent and was cultured in MEM—with 20% FBS and 5 ng/ml GM-CSF. Fresh and frozen human bone marrow CD34+ cells were obtained from Stemcell Technologies (Vancouver, B.C., Canada). FACS analysis for CD34 antigen revealed a purity >98%.
Human Progenitor CD34+ Cell Cultures.
Human bone marrow CD34+ cells were grown in STEM-media (Stemcell Technologies), which includes Isocove modified Dulbecco's medium supplemented with human transferrin, insulin, bovine serine albumin, human low density lipoprotein and glutamine, in the presence of 100 ng/ml human recombinant thrombopoietin (TPO) for the first 4 days, followed by a combination of 100 ng/ml TPO, IL3, and SCF (cytokine mixture CC-200, Stemcell Technologies). The initial cell density was 100,000 cells/ml; three times a week, the cell density was adjusted to 100,000 to 200,000 cells/ml. To increase the purity of the cells for microarray analysis, cell sorting was performed at day 10 of culture. Cells were incubated on ice for 45 minutes with anti-human CD34+, anti-human CD41+, anti-human CD61+, and their respective isotypes. After washing twice with PBS 3% FBS, cells were sorted using a FACS Aria sorting machine in bulk in two separate populations; CD34−CD61+ and CD34+CD61+ cells for culture and RNA extraction. The purity of the sorted populations was greater than 95%.
Megakaryocytes Characterization.
Cytospin preparations of CD34+ progenitors in culture were performed and stained with May-Grunwald Giemsa at different time points during the megakaryocytic differentiation induction. For FACS analysis, the primary antibodies that were used were as follows: CD41A, CD61A, CD42B, and CD34 with their respective isotypes (BD Pharmingen, San Diego, Calif.). Cytometric studies were performed as previously described (Tajima, S., et al. (1996) J. Exp. Med. 184, 1357-1364) using a FACScalibur (BD Biosciences) and the CELLQUEST software (BD Biosciences).
RNA Extraction, Northern Blotting and miRNA Microarray Experiments.
Procedures were performed as described in detail elsewhere (Liu, C. G., et al. (2002) Proc. Natl. Acad. Sci. USA 101, 9740-9744). Raw data were normalized and analyzed in GENESPRING 7.2 software (zcomSilicon Genetics, Redwood City, Calif.). Expression data were median-centered by using both GENESPRING normalization option and global median normalization of the BIOCONDUCTOR package (www.bioconductor.org) with similar results. Statistical comparisons were done by using the GENESPRING ANOVA tool, predictive analysis of microarray (PAM) and the significance analysis of microarray (SAM) software (www-stat.stanford.edu/ ̃tibs/SAM/index.html).
Reverse Transcriptase PCR(RT-PCR) and Real Time PCR.
Total RNA isolated with Trizol reagent (Invitrogen, Carlsbad, Calif.) was processed after DNAase treatment (Ambion, Austin, Tex.) directly to cDNA by reverse transcription using Superscript II (Invitrogen). Comparative real-time PCR was performed in triplicate. Primers and probes were obtained from Applied Biosystems (Foster City, Calif.) for the following genes: HOXA1, HOXA3, HOXB4, HOXB5, and HOXD10. Gene expression levels were quantified by using the ABI Prism 7900 Sequence detection system (Applied Biosystems). Normalization was performed by using the 18S RNA primer kit. Relative expression was calculated by using the computed tomography (CT) method. RT-PCR also was performed by using the following oligonucleotide primers:









MAFB FW;



(SEQ ID NO: 499)



5′-AACTTTGTCTTGGGGGACAC-3′;



 



MAFB RW;



(SEQ ID NO: 500)



5′-GAGGGGAGGATCTGTTTTCC-3′;



 



HOXA1 FW;



(SEQ ID NO: 501)



5′-CCAGGAGCTCAGGAAGAAGA GAT-3′;



and



 



HOXA1 RW;



(SEQ ID NO: 502)



5′-CCCTCTGAGGCATCTGATTGGGTTT-3′.






Real-Time Quantification of miRNAs by Stem-Loop RT-PCR.
Real time-PCR for pri-miRNAs 10a, miR15a, miR16-1, miR-130a, miR-20, miR-106, miR-17-5, miR-181b, miR-99a, and miR-126 were performed as described (Chen, C., et al. (2005) Nucl. Acids Res. 33, e179. 18S was used for normalization. All reagents and primers were obtained from Applied Biosystems.
Bioinformatics.
miRNA target prediction of the differentially expressed miRNAs was performed by using TARGETSCAN (www.genes.mit.edu/targetscan), MIRANDA (www.mskc.miranda.org), and PICTAR (www.pictar.bio.nyu.edu) software.
Cell Transfection with miRNA Precursors.
miRNA precursors miR-10a and miR-130a were purchased from Ambion. Five million K562 cells were nucleoporated by using Amaxa (Gaithesburg, Md.) with 5 μg of precursor oligonucleotides in a total volume of 10 ml. The expression of the oligonucleotides was assessed by Northern blots and RT-PCR as described.
Luciferase Reporter Experiments.
The 3′ UTR segments containing the target sites for miR-10a and miR-130a from HOXA1 and MAFB genes, respectively, were amplified by PCR from genomic DNA and inserted into the pGL3 control vector (Promega, Madison, Wis.), by using the XbaI site immediately downstream from the stop codon of luciferase. The following oligonucleotide primer sets were used to generate specific fragments:









MAFB FW



(SEQ ID NO: 503)



5′-GCATCTAGAGCACCCCAGAGGAGTGT-3′;



 



MAFB RW



(SEQ ID NO: 504)



5′-GCATCTAGACAAGCACCATGCGGTTC-3′;



 



HOXA1 FW



(SEQ ID NO: 505)



5′-TACTCTAGACCAGGAGCTCAGGAAGA-3′;



and



 



HOXA1 RW



(SEQ ID NO: 506)



5′-MCATTCTAGATGAGGCATCTGATTGGG-3′.






We also generated two inserts with deletions of 5 bp and 9 bp, respectively, from the site of perfect complementarity by using the QuikChange XL-site directed Mutagenesis Kit (Stratagene, La Jolla, Calif.). Wild type (WT) and mutant insert were confirmed by sequencing.
Human chronic myeloid leukemia (CML) in megakaryoblastic crisis cell line (MEG-01) was cotransfected in six-well plates by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol with 0.4 μg of the firefly luciferase report vector and 0.08 μg of the control vector containing Renilla luciferase, pRL-TK (Promega). For each well, 10 nM of the premiR-130a and premiR-10a precursors (Ambion) were used. Firefly and Renilla luciferase activities were measured consecutively by using the dual luciferase assays (Promega) 24 hours after transfection.
Western Blots.
Total and nuclear protein extracts from K562 cells transfected with miR-10a and miR-130a, as well as CD34+ cells at different stages of megakaryocytic differentiation were extracted by using RIPA buffer or Nuclear extraction Kit (Pierce, Rockford, Ill.). Protein expression was analyzed by Western blotting with the following primary antibodies: MAFB (Santa Cruz Biotechnology, Santa Cruz, Calif.), HOXA1 (R&D Systems, Minneapolis, Minn.), β-Actin and Nucleolin (Santa Cruz Biotechnology). Appropriate secondary antibodies were used (Santa Cruz Biotechnology).
Example 1
miRNA Expression During In Vitro Megakaryocytic Differentiation of CD34+ Progenitors
Using a combination of a specific megakaryocytic growth factor (thrombopoietin) and nonspecific cytokines (SCF and IL-3), we were able to generate in vitro pure, abundant megakaryocyte progeny from CD34+ bone marrow progenitors suitable for microarray studies (FIG. 4). Total RNA was obtained for miRNA chip analysis from three different CD34 progenitors at baseline and at days 10, 12, 14 and 16 of culture with cytokines. We initially compared the expression of miRNA between the CD34+ progenitors and the pooled CD34+ differentiated megakaryocytes at all points during the differentiation process. 17 miRNAs (Table 1) that are sharply down regulated during megakaryocytic differentiation were identified. There were no statistically significant miRNAs upregulated during megakaryocytic differentiation. Using predictive analysis of microarray (PAM), we identified 8 microRNAs that predicted megakaryocytic differentiation with no misclassification error: miR-10a, miR-10b, miR-30c, miR-106, miR-126, miR-130a, miR-132, and miR-143. All of these miRNAs, except miR-143, are included in the 17 miRNAs identified by significance analysis of microarray (SAM). Northern blots and real-time PCR for several miRNAs confirmed the results obtained by miRNA chip analysis (FIG. 1).
Because we found mainly downregulation of miRNAs during megakaryocytopoiesis, we hypothesized that these miRNAs may unblock target genes involved in differentiation. In line with this hypothesis, miRNAs that are sharply downregulated in our system are predicted to target genes with important roles in megakaryocytic differentiation. Among the transcription factors with well-known function in megakaryocytopoiesis, RUNX-1 (Elagib, K. E., et al. (2003) Blood, 101:4333-4341), Fli-1 (Athanasoiu, M., et al. (1996) Cell Growth Differ. 7, 1525-1534), FLT1 (Casella, I., et al. (2003) Blood 101, 1316-1323), ETV6 (Hock, H., et al. (2004) Genes Dev. 18:2336-2341), TAL1
(Begley, C. G., and Green, A. R. (1999) Blood, 93:2760-2770), ETS1 (Jackers, P., et al. (2004) J. Biol. Chem. 279:52183-52190) and CRK (Lannutti, B. J., et al. (2003) Exp. Hematol. 12:1268-1274) are putative targets for several miRNAs downregulated in differentiated megakaryocytes. Moreover, each of these transcription factors has more than one miRNA predicted to be its regulator. For example, RUNX1 (AML1) is predicted to be the target of miR-106, miR-181b, miR-101, let7d and the miR-17-92 cluster. The multiplicity of miRNAs predicted to target AML1 suggests a combinatorial model of regulation.
We then looked at the temporal expression of miRNAs during the megakaryocytic differentiation process from CD34+ progenitors. We focused on miRNAs that have been described in hematopoietic tissues, such as miR-223, miR-181, miR-155, miR-142, miR-15a, miR-16, miR-106 and the cluster of miR-17-92 (FIG. 5). We found sequential changes in the expression of miR-223. Initially, miR-223 is downregulated during megakaryocytic differentiation, but after 14 days in culture, its expression returns to levels comparable with that of CD34 progenitors (FIG. 1C). The miR-15a and miR-16-1 cluster also follows the same pattern of expression as miR-223 (FIG. 1D), whereas miR-181b, miR-155, miR-106a, miR-17, and miR-20 were downregulated during differentiation (FIG. 6). The temporal variation of the expression of miR-223 and miR-15a/mir-16-1 suggests a stage-specific function.
Table 2. miRNAs downregulated during in vitro CD34+ megakaryocytic differentiation. All differentially expressed miRNAs have q value <0.01 (false-positive rate).







TABLE 2







miRNAs downregulated during in vitro CD34+ megakaryocytic


differentiation. All differentially expressed miRNAs have q value <0.01


(false-positive rate).












Chromosomal
T-test
Fold



miRNA
Location
(†)
Change
Putative targets














hsa-mir-010a*
17q21
−9.10
50.00
HOXA1, HOXA3,






HOXD10, CRK, FLT1


hsa-mir-126*
9q34
−2.73
8.33 
CRK , EVI2, HOXA9, 






MAFB, CMAF


hsa-mir-106*
xq26.2
−2.63
2.86
TAL1, FLT1, SKI,






RUNX1, FOG2, FLI,






PDGFRA, CRK


hsa-mir-010b*
2q31
−2.17
11.11
HOXA1, HOXA3,






HOXD10, ETS-1,






CRK, FLT1


hsa-mir-130a*
11q12 
−2.08 
4.76
MAFB, MYB, FOG2,






CBFB, PDGFRA,






SDFR1, CXCL12


hsa-mir-130a-
11q12
−2.07
7.69
NA±


prec*






hsa-mir-124a
8q23
−1.81
2.78
TAL1, SKI, FLT1,






FOG2, ETS-1, CBFB,






RAF1, MYB


hsa-mir-032-
9q31
−1.76
3.57
NA±


prec






hsa-mir-101
1p31.3
−1.75
3.33
TAL1, CXCL12,






MEIS1, MEIS2,






ETS-1 RUNX1, MYB


hsa-mir-30c
6q13
−1.71
2.56
CBFB, MAFG,






HOXA1, SBF1,






NCOR2, ERG


hsa-mir-213*
1q31.3
−1.69
2.38
MAX- SATB2


hsa-mir-132- 
17p13
−1.67
4.17
NA±


prec






hsa-mir-150*
19q13.3
−1.63
5.26
MYB, SDFR1


hsa-mir-020
13q31
−1.62
2.17
TAL1, SKI, RUNX-1,






FLT1, CRK, FOG2,






RARB


hsa-mir-339
7p22
−1.60
3.03
SKI, ETV6, GATA2,






FLT1, RAP1B, JUNB,






MEIS2


hsa-let-7a
9q22
−1.58
2.94
HOXA1, HOXA9,






MEIS2, ITGB3, PLDN


hsa-let-7d
9q22
−1.56
2.17
HOXA1, HOXD1,






ITGB3, RUNX1,






PDGFRA


hsa-mir-181c
19p13
−1.55
2.50
RUNX-1, KIT,






HOXA1, MEIS2,






ETS-1 ETV6,






PDGFRA


hsa-mir-181b
1q31.3
−1.53
2.13
RUNX-1, KIT,






ITGA3, HOXA1,






MEIS2, ETS-1,






SDFR1,


hsa-mir-017
13q31
−1.38
1.82
TAL1 SKI, FLT1,






RUNX1, CRK, FOG1,






ETS-1, MEIS1





† t test p < 0.05.


*These miRNAs were identified by PAM as predictors of a megakaryocytic class with the lowest misclassification error. All, except miR-143 are downregulated during megakaryocytic differentiation.


NA±: miRNA precursor sequence that does not contain the mature miRNA, therefore no putative target is shown.






Example 2
MAFB Transcription Factor is a Target of miR-130a
By using three target prediction algorithms (TARGETSCAN (www.genes.mit.edu/targetscan), MIRANDA (www.microrna.org/miranda_new.html), and PICTAR (www.pictar.bio.nyu.edu)), we identified that miR-130a is predicted to target MAFB, a transcription factor that is upregulated during megakaryocytic differentiation and induces the GPIIb gene, in synergy with GATA1, SP1 and ETS-1 (Sevinsky, J. R., et al. (2004) Mol. Cell. Biol. 24, 4534-4545). To investigate this putative interaction, first, we examined MAFB protein and mRNA levels in CD34+ progenitors at baseline and after cytokine stimulation (FIG. 2A). We found that the MAFB protein is upregulated during in vitro megakaryocytic differentiation. Although the mRNA levels for MAFB by PCR increase with differentiation, this increase does not correlate well with the intensity of its protein expression. The inverse pattern of expression of MAFB and miR-130a suggested in vivo interaction that was further investigated.
To demonstrate a direct interaction between the 3′ UTRs of MAFB with miR-130a, we inserted the 3′ UTR regions predicted to interact with this miRNA into a luciferase vector. This experiment revealed a repression of about  ̃60% of luciferase activity compared with control vector (FIG. 2B). As an additional control experiment, we used a mutated target mRNA sequence for MAFB lacking five of the complementary bases. As expected, the mutations completely abolished the interaction between miR-130a and its target 3′UTRs (FIG. 2B).
We also determined the in vivo consequences of overexpressing miR-130a on MAFB expression. The pre-miR-130a and a negative control were transfected by electroporation into K562 cells, which naturally express MAFB and lack miR-130a. Transfection of the pre-miR-130a, but not the control, resulted in a decrease in the protein levels at 48 hours (FIG. 2C). Northern blotting confirmed successful ectopic expression of miR-130a in K562 cells (FIG. 7).
Example 3
MiR-10a Correlates with HOXB Gene Expression
It has been reported that in mouse embryos, miR-10a, miR-10b, and miR-196 are expressed in HOX-like patterns (Mansfield, J. H., et al. (2004) Nature 36, 1079-1083) and closely follow their “host” HOX cluster during evolution (Tanzer, A., et al. (2005) J. Exp. Zool. B Mol. Dev. Evol. 304B, 75-85). These data suggest common regulatory elements across paralog clusters. MiR-10a is located at chromosome 17q21 within the cluster of the HOXB genes (FIG. 8) and miR-10b is located at chromosome 2q31 within the HOXD gene cluster. To determine whether the miR-10a expression pattern correlates with the expression of HOXB genes, we performed RT-PCR for HOXB4 and HOXB5, which are the genes located 5′ and 3′, respectively, to miR-10a in the HOXB cluster. As shown in FIG. 8, HOXB4 and HOXB5 expression paralleled that of miR-10a, suggesting a common regulatory mechanism.
Example 4
MiR-10a Downregulates HOXA1
We determined by miRNA array and Northern blot that miR-10a is sharply down-regulated during megakaryocytic differentiation. Interestingly, we found several HOX genes as putative targets for miR-10a (Table 2). We thus investigated whether miR-10a could target a HOX gene. We performed real-time PCR for the predicted HOX targets of miR-10: HOXA1, HOXA3, and HOXD10. After normalization with 18S RNA, we found that HOXA1 mRNA is upregulated 7-fold during megakaryocytic differentiation compared with CD34 progenitors (FIG. 3A; see also FIG. 9). HOXA1 protein levels were also upregulated during megakaryocytic differentiation (FIG. 3B). These results are in sharp contrast with the downregulation of miR-10a in megakaryocytic differentiation, suggesting that miR-10a could be an inhibitor of HOXA1 expression. To demonstrate a direct interaction of miR-10a and the 3′ UTR sequences of the HOXA1 gene, we carried out a luciferase reporter assay as described in Material and Methods. When the miRNA precursor miR-10a was introduced in the MEG01 cells along with the reporter plasmid containing the 3′ UTR sequence of HOXA1, a 50% reduction in luciferase activity was observed (FIG. 3C). The degree of complementarity between miR-10a and the HOXA1 3′ UTR is shown in FIG. 3D, as predicted by PICTAR (www.pictar.bio.nyu.edu).
To confirm in vivo these findings, we transfected K562 cells with the pre-miR-10a precursor using nucleoporation and measured HOXA1 mRNA expression by RT-PCR and HOXA1 protein levels by Western blotting. Successful ectopic expression of miR-10a was documented by Northern Blot (FIG. 3E). A significant reduction at the mRNA and protein levels for HOXA1 was found for K562 cells transfected with the miR-10a precursor but not with the negative control (FIGS. 3F and 3G). These data indicate that miR-10a targets HOXA1 in vitro and in vivo.
It has been reported that miR-196 induces cleavage of HOXB8 mRNA, pointing to a posttranscriptional restriction mechanism of HOX gene expression (Yekta, S., et al. (2004) Science, 304:594-596). Contrary to the miR-196-HOXB8 interaction, where an almost perfect complementarity exists, the degree of pairing between miR-10a and the human HOXA1 3′ UTR is suboptimal (FIG. 4). Although our results indicated target mRNA degradation, further studies are needed to determine whether cleavage or translational repression is the primary mechanism of downregulation of the HOXA1 gene in this system. A previous study using microarray analysis showed that a large number of target mRNA genes are downregulated by miRNA at the level of transcription (Lim, L. P., et al. (2005) Nature: 433, 769-771). These data raise the question whether target degradation is a consequence of translational repression and subsequent relocalization of the miR-target complexes to cytoplasmic processing bodies or is a primary event (Pillai, R. (2005) RNA 11, 1753-1761).
Example 5
miRNA Profiling in Acute Megakaryoblastic Leukemia (AMKL) Cell Lines
After the identification of the microRNA expression profile of CD34+ cells during megakaryocytic differentiation, we then investigated miRNA expression in AMKL cell lines with the goal to identify differentially expressed miRNAs that could have a pathogenic role in megakaryoblastic leukemia. We initially compared miRNA expression in four AMKL cell lines with that of in vitro CD34+-differentiated megakaryocytes. Using significance analysis of microarray (SAM), we identified 10 miRNAs upregulated in AMKL cell lines compared with that of CD34 in vitro-differentiated megakaryocytes (Table 3; see also Table 4). These miRNAs are as follows (in order of the fold increase with respect to differentiated megakaryocytes): miR-101, miR-126, miR-99a, miR-99-prec, miR-106, miR-339, miR-99b, miR-149, miR-33 and miR-135. Results were validated by RT-PCR as shown in FIG. 10. Using PAM, we compared miRNA expression in CD34+ cells with in vitro-differentiated megakaryocytes and AMKL cell lines (FIG. 10). Interestingly, we found five miRNAs involved in the megakaryocytic differentiation signature (miR-101, miR-126, miR-106, miR-20, and miR-135) that were upregulated in the leukemic cell lines (Tables 3, 5 and 6). Whether this profile represents merely a differentiation state of the cells or has a truly pathogenic role remains to be elucidated. Supporting the second hypothesis, miR-106, miR-135, and miR-20 are predicted to target RUNX1, which is one of the genes most commonly associated with leukemia (Nakao, M., et al. (2004) Oncogene 125, 709-719). Moreover, mutations of RUNX1 have been described in familial thrombocytopenias with a propensity to develop acute myeloid leukemia (Song, W. J., et al. (1999) Nat. Genet. 23, 166-175).
Table 3. microRNAs upregulated in acute megakaryoblastic cell lines compared with in vitro-differentiated megakaryocytes.











TABLE 3






Chromosomal
t test
Fold



microRNA
Location
Score
Change
Putative Targets



















hsa-mir-101
1p31.3
6.14
11.85
MEIS2, RUNX1, ETS-1, C-MYB,






FOS, RARB, NFE2L2


hsa-mir-126
9q34
4.91
11.97
V-CRK


hsa-mir-099a
21q21
3.30
6.83
HOXA1, EIF2C, FOXA1


hsa-mir-099b-
21q21
2.85
7.59
NA


prec


hsa-mir-106
xq26.2
2.79
3.33
FLT1, SKI, E2F1, NCOA3,






PDGFRA, CRK


hsa-mir-339
7p22
2.58
3.36
HOXA1, FLT1, PTP4A1, RAP1B


hsa-mir-099b
19q13
2.46
4.19
HOXA1, MYCBP2


hsa-mir-149
2q37
2.29
3.53
RAP1A, MAFF, PDGFRA, SP1,






NFIB


hsa-mir-033
2q13
2.27
3.23
PDGFRA, HIF1A, MEIS2


hsa-mir-135
3p21
2.12
3.97
SP1, HIF1A, SP3, HNRPA1,






HOXA10, RUNX1









All the miRNAs have a q value <0.01 (false discovery rate).
The same miRNAs, except miR-339 and miR-149, were found by using PAM to predict a megakaryoblastic leukemia class with no misclassification error.\
The results described herein demonstrate that there is a downregulation of miRNAs during megakaryocytopoiesis. Hypothetically, the downregulation of miRNAs unblocks target genes involved in differentiation. In line with this hypothesis, miRNAs that are sharply downregulated in our system are predicted to target genes with important roles in megakaryocytic differentiation. Thus, we have shown that miR-130a targets MAFB and miR-10a modulates HOXA1. The fact that we found several differentially expressed miRNAs during differentiation and leukemia that are predicted to target HOXA1 suggests a function for HOXA1 in megakaryocytopoiesis. Loss and gain studies will ultimately be needed to define the role of HOXA1 in this differentiation process. Our findings delineate the expression of miRNAs in megakaryocytic differentiation and suggest a role for miRNA modulation of this lineage by targeting megakaryocytic transcription factors. Furthermore, in megakaryoblastic leukemia cell lines, we have found inverse expression of miRNAs involved in normal megakaryocytic differentiation. These data provide a starting point for future studies of miRNAs in megakaryocytopoiesis and leukemia.
Table 4. Signature of megakaryocytic differentiation.











TABLE 4








CD34
Megakaryocytic



microRNA
Expression
Expression









hsa-mir-010a
up
Down



hsa-mir-126
up
Down



hsa-mir-130a-prec
up
Down



hsa-mir-010b
up
Down



hsa-mir-106
up
Down



hsa-mir-130a
up
Down



hsa-mir-132
up
Down



hsa-mir-30c
up
Down



hsa-mir-143-prec
Down
up










PAM selected microRNAs with a very low misclassification error.
Table 5 Signature of megakaryoblastic leukemia cell lines











TABLE 5








Level of




t

Expres-



test
Fold
sion in


MicroRNA
Score
Change
AML M7
Putative Targets



















hsa-mir-101-
6.14
11.85
up
MEIS2, RUNX1, C-MYB,






FOS, RARb, NFE2L2


hsa-mir-126
4.91
11.97
up
V-CRK


hsa-mir-099a
3.30
6.83
up
HOXA1, EIF2C, FOXA1


hsa-mir-095


up
SHOX2


hsa-mir-033
2.27
3.23
up
PDGFRA, HIF1A, MEIS2


hsa-mir-135
2.12
3.97
up
SP1, HIF1A, SP3, HNRPA1,






HOXA10, RUNX1


hsa-mir-099b
2.85
7.59
up
HOXA1, MYCBP2


hsa-mir-339
2.58
3.36
up
HOXA1, FLT1, PTP4A1,






RAP1B


hsa-mir-106
2.79
3.33
up
HOXA1, EIF2C, FOXA1


hsa-mir-124a
2.07
2.78
up
SDFR1, RXRa


hsa-mir-155


down
ETS-1


hsa-mir-020
2.00
3.09
up
TAL1, SKI, RUNX-1, FLT1,






CRK, FOG2, RARB


hsa-mir-025
1.98
4.24
up
GATA2,


hsa-mir-140


down
GATA1









PAM selected microRNAs. The fold change of miRNA expression is shown alongside t test score (SAM) and putative targets.

Table 6 Three class analysis showing the different regulated microRNAs among the three cell types: CD34+ progenitors, acute megakaryoblastic leukemia cell lines (AMKL) and in vitro-differentiated megakaryocytes.











TABLE 6








AML M7
In Vitro-



Chromo-

cell
differentiated



somal
CD34+
lines
Megakaryocytes


microRNA
Location
Score
score
Score



















hsa-mir-010a
17q21
1.0198
0
−0.3562


hsa-mir-101
1p31.3
0
0.814
−0.432


hsa-mir-126
9q34
0.0621
0.4882
−0.4514


hsa-mir-099a
21q21
0
0.4685
−0.2875


hsa-mir-033
22q13
0
0.4258
−0.2294


hsa-mir-095
4p16
0
0.4142
−0.3567


hsa-mir-010b
2q31
0.3308
0
0


hsa-mir-155
21q21
0
−0.3217
0


hsa-mir-130a
11q12
0.2755
0
0


hsa-let-7d
9q22
0.263
−0.274
0


hsa-mir-099b-prec
21q21
0
0.266
−0.1078


hsa-mir-135-2-prec
12q23
0
0.2279
−0.2566


hsa-mir-339
7p22
0
0.2456
−0.1176


hsa-mir-099b
19q13
0
0.2275
−0.1025


hsa-mir-106
xq26
0
0.0575
−0.1891


hsa-let-7c
21q21
0.0289
−0.1753
0


hsa-mir-148
7p15
0
−0.1748
0


hsa-mir-132-prec
17p13
0.1721
0
0


hsa-mir-020
13q31
0
0.0374
−0.1509









There are three patterns of miRNA expression among the three different cell types. The first pattern is defined by miRNA highly expressed in CD34+ cells and downregulated in AMKL and differentiated megakaryocytes. miR-10a and miR-130a follow this pattern of expression; however, miR-10a is upregulated in AMKL relative to differentiated megakaryocytes. The second pattern is miRNA that is upregulated in AMKL, downregulated in CD34+ cells and differentiated megakaryocytes and includes the following miRNAs: miR-126, miR-99, miR-101, let 7A, and miR-100. The last two miRNAs are equally expressed in CD34+ and differentiated megakaryocytes, rather than showing a gradual decline in expression, as evidenced by miR-126, miR-99 and miR-101. The last pattern includes miRNA-106 and miRNA-135-2, which are upregulated in CD34+ cells and AMKL, but low in differentiated megakaryocytes.
MicroRNAs are a highly conserved class of non-coding RNAs with important regulatory functions in proliferation, apoptosis, development and differentiation. As described herein, to discover novel regulatory pathways during megakaryocytic differentiation, we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34+ hematopoietic progenitors. One major finding was downregulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20. Without wishing to be bound to any theory, it is believed that the downregulation of microRNAs unblocks target genes involved in differentiation. It was confirmed in vitro and in vivo that miR-130a targets the transcription factor MAFB, which is involved in the activation of the GPIIB promoter, a key protein for platelet physiology. In addition, it was shown that miR-10a expression in differentiated megakaryocytes is inverse to that of HOXA1, and HOXA1 is a direct target of miR-10a. Finally, the microRNA expression of megakaryoblastic leukemic cell lines was compared to that of in vitro-differentiated megakaryocytes and CD34+ progenitors. This analysis revealed upregulation of miR-101, miR-126, miR-99a, miR-135, and miR-20 in the cancerous cell line. The data and results described herein delineate the expression of microRNAs during megakaryocytopoiesis and demonstrate a regulatory role of microRNAs in this process by targeting megakaryocytic transcription factors.
The relevant teachings of all publications cited herein that have not explicitly been incorporated by reference, are incorporated herein by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
While the invention has been described with reference to various and preferred embodiments, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the essential scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed herein contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the claims.

## Claims

1. A method of decreasing expression of a transcription factor gene product from the Maf family, also known as protooncogene c-Maf or V-maf musculoaponeurotic fibrosarcoma oncogene homolog, (MAFB in a subject having a cancer and/or myeloproliferative disorder associated with an overexpression of a MAFB gene product, comprising
administering an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof to the subject sufficient to decrease expression of the MAFB gene product in the subject, wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML).

2. The method of claim 1, wherein the at least one miR-130a gene product or isolated variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product.

3. The method of claim 1, wherein the cancer and/or myeloproliferative disorder is a leukemia.

4. The method of claim 3 wherein the leukemia is acute myeloid leukemia.

5. The method of claim 4, wherein the acute myeloid leukemia is acute megakaryoblastic leukemia.

6. The method of claim 1, wherein the cancer is multiple myeloma.

7. The method of claim 1, wherein the cancer and/or a myeloproliferative disorder is chronic myelogenous leukemia (CML).

8. The method of claim 1, wherein the subject is a human.